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Abstract
Malaria is a mosquito-borne disease caused by parasites of the obligate in-
tracellular Apicomplexa phylum the most deadly of which, Plasmodium fal-
ciparum, prevails in Africa. Malaria imposes a huge health burden on the
world’s most vulnerable populations, claiming the lives of nearly one mil-
lion children and pregnant women each year. Although there is keen interest
in eradicating malaria, we do not yet have the necessary tools to meet this
challenge, including an effective malaria vaccine and adequate vector control
strategies. Here we review what is known about the mechanisms at play in
immune resistance to malaria in both the human and mosquito hosts at each
step in the parasite’s complex life cycle with a view toward developing the
tools that will contribute to the prevention of disease and death and, ulti-
mately, to the goal of malaria eradication. In so doing, we hope to inspire
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INTRODUCTION
Malaria is a deadly disease. Each year, P. falciparum infections cause approximately 225 million
cases of malaria and nearly one million deaths, most of which are among African children and
pregnant women (1). P. falciparum is transmitted from person to person by the bite of an infected
female Anopheles mosquito, primarily Anopheles gambiae in Africa. A. gambiae is an extraordinarily
efficient, highly adapted vector that feeds nearly exclusively on humans and has a long life span.
P. falciparum has a complex life cycle that involves critical developmental stages in both the
human and mosquito hosts. We now appreciate that both the human and mosquito immune
systems mount responses to P. falciparum infections and that these responses dictate the course
of the disease in humans and the ability of the mosquito to transmit the parasite. The striking
feature of immune resistance to malaria in humans is that it develops only after years in malaria-
endemic areas, even in areas of high transmission where children may be exposed to hundreds of
infectious mosquito bites each year (2). In areas of intense transmission, children become resistant
to the most severe forms of malaria by the age of five or so; however, they remain susceptible to
uncomplicated episodes of febrile malaria until late childhood or early adolescence, when they
transition to a malaria-resistant state and rarely suffer from clinical malaria (3). The length of
time required to develop clinical resistance to malaria is remarkable when compared with the
rapid acquisition of immunity to many viral diseases including measles, rubella, and smallpox after
a single infection. Even though resistance to the disease manifestations of malaria is eventually
acquired with cumulative malaria exposure, resistance to infection per se is rarely if ever achieved,
such that adults living in endemic areas frequently have asymptomatic blood-stage infections (3).
Thus, the acquisition of immunity to malaria in humans is complex, involving early resistance
to severe disease, followed by resistance to uncomplicated disease, but rarely, if ever, involving
resistance to infection. In contrast to the human host that combats malaria through both adaptive
and innate immune mechanisms, the mosquito has only innate immune mechanisms to control
parasite infection, but these are remarkably complex and may provide insights into mechanisms
at play in the human host.
In this review, we describe our current understanding of the acquisition of immunity to both
uncomplicated and severe malaria in humans and the nature of the mosquito’s innate immune
response to parasite infection.We focus our discussion on P. falciparummalaria, although another
Plasmodium species, P. vivax, is an important pathogen outside of Africa, and we refer the reader
to an excellent review of the acquisition of immunity to this parasite (4). At present we do not have
a malaria vaccine (5) or adjunctive therapies to treat severe disease (6), nor do we have adequate
vector control strategies (7) that would decrease disease and death and aid eradication efforts. A
clearer understanding of human and mosquito immunity to this deadly infection will undoubtedly
contribute to the development of these tools. We preface this description with a discussion of
the evolution of P. falciparum and its human host to highlight the influence of host and parasite
genetics on the outcome of Plasmodium infections. Given recent renewed calls for eradication of
malaria, we consider how a better understanding of the cellular and molecular basis of human and
mosquito immune mechanisms in malaria may contribute to eradication efforts.
A RENEWED CALL FOR MALARIA ERADICATION
In the fall of 2007 at the Gates Malaria Forum, Bill and Melinda Gates proposed a sweeping new
plan to eradicatemalaria (8).Theproposal shocked themalaria researchfield as there hadbeen little
discussion of eradication since earlier programs launched in the 1950s had failed. The proposal to
eradicate malaria immediately begged the question: Do we have the necessary tools to even make
an attempt? For smallpox, an eradication success story, and for polio, a virus that has been targeted
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for eradication, the only tool necessary was a vaccine. At present, we do not have a licensed vaccine
that would block malaria transmission, and the front-running malaria vaccine candidate, RTS,S,
appears to confer only short-lived, partial efficacy (30–50%) against clinical malaria in African
infants and children (9). We currently have effective antimalarial drugs that treat the blood stage
of the disease and thus decrease transmission (6). However, explosive malaria epidemics would be
possible prior to eradication as resistance to these drugs emerges, which seems inevitable (6).
The Gates proposal for malaria eradication was based on the idea that each incremental
improvement in malaria control would be additive, ultimately resulting in eradication. Experience
teaches us otherwise. Attempts at eradication in the 1950s were driven by theMacdonald equation
for vector control that predicted that if mosquito populations could be reduced to critical levels,
malaria transmission would be prevented (10). However, in reality even with the wonder of the
insecticide DDT, it was not possible to stop malaria transmission in Africa (11). Even in areas of
relatively low transmission such as India, elimination was not achieved through mosquito control.
In India, malaria nearly disappeared in the 1960s but then returned, reaching over six million cases
in 1976 (12). The lesson drawn is that wherever mosquitoes persist, malaria epidemics are always
possible. Indeed, it has been calculated that when the reproductive rate (a complicated factor
that takes into account a variety of parameters including the number of infected mosquitoes,
how often they feed, and how long they live) reaches 100, a rate not uncommon in many areas
in Africa, the prevalence of infection can rapidly increase, going from 0.1% to 50% infected
individuals in a mere 100 days (13).
Given that conventional control methods have not succeeded in blockingmalaria transmission,
other tools will need to be developed. Transmission-blocking vaccines that induce antibodies to
parasite proteins that are essential in parasite development in themosquito are under development.
Thus far, however, such vaccines have not shown the ability to induce long-lasting transmission-
blocking antibodies in humans (5). An alternative approach is to modify the mosquito population
so that it has no vector capacity. Suchmodifications clearly face enormous challenges andwill likely
require years of research to identify genes that, if modified, would lead to refractoriness and then to
develop genetic techniques to manipulate mosquito populations. Nevertheless, such a long-term
effort may be worthwhile. Without the ability to modify mosquito populations, eradication may
simply never be possible.
Despite the focus of the Gates Foundation on developing tools for eradication, there remains
a desperate need for a vaccine that would reduce malaria disease and death, even one that does
not block transmission. Knowledge of the mechanisms underlying the acquisition of immunity to
natural malaria infection will undoubtedly aid in the development of such a vaccine.
THE EVOLUTIONARY DANCE OF P. FALCIPARUM AND ITS HOSTS
In discussing the immune mechanisms at play in controlling malaria, it is helpful to consider that
P. falciparum is estimated to be greater than 100,000 years old, as old as humans (14), suggesting
that the human immune system and the parasite coevolved. Because of the enormous selective
pressure imposed by the high mortality resulting from P. falciparum infections in children and
pregnant women, malaria has had a tremendous impact in shaping the human genome, perhaps
more than any other pathogen (15). One of the best-studied examples of the evolutionary pressure
of P. falciparum on the human genome is the hemoglobin S (HbS) variant. In the homozygous
state, HbS results in sickle cell anemia that is lethal in West African children. Nonetheless, HbS
is maintained at a frequency of 10–20% because in the heterozygous state HbS confers protection
against severe malaria (16). One theme that runs throughout this review is that P. falciparum likely
had a significant influence in shaping the immune mechanisms in both the human and mosquito
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hosts, which has allowed its persistence in both hosts as well as its transmission, presumably
in exchange for some advantage to its hosts. As part of the coevolution of P. falciparum and
its hosts, the parasite has likely evolved a myriad of mechanisms to evade and disable its hosts’
immune responses. The P. falciparum genome contains approximately 5,400 genes (17); however,
remarkably, we are aware of only a handful of mechanisms in humans and in mosquitoes that
impact host immunity, leaving a great deal for discovery.
P. FALCIPARUM LIFE CYCLE
P. falciparum has a complex life cycle involving both human and mosquito hosts (Figure 1).
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prepares to take a blood meal. Its saliva contains a highly motile differentiated form of the P. falci-
parum parasite called a sporozoite, and a small number of these (10–100) are injected in the skin,
where they may remain for hours if not days (18). The infecting sporozoites cross the endothelium
of the capillaries in the skin, enter the blood, and travel to the liver. In the liver, the sporozoites
traverse Kupffer cells and hepatocytes, invading a small number of the latter (19). Within hepa-
tocytes, the sporozoites replicate over a week’s time, increasing in number up to 40,000-fold, and
differentiate, giving rise to a large number of asexual blood-stage parasites called merozoites.
Up to this point in the parasite’s life cycle, individuals are unaware that they are infected because
there are no clinical symptoms. Merozoites are released into the bloodstream via the budding
of parasite-filled, hepatocyte-derived vesicles called merosomes, clearing the liver of parasites
(20). In the bloodstream, free merozoites begin 48-h cycles of invasion of red blood cells (RBCs),
replication, RBC rupture, and release of merozoites, beginning again with invasion of RBCs. Par-
asitemia often exceeds densities of 50,000 infected RBCs (iRBCs) per microliter of blood. Various
parasite products are released upon iRBC lysis that correlate with the onset of malaria symptoms
including headaches, fever, and lethargy. During RBC infection, merozoites dramatically remodel
the RBC membrane, expressing several parasite-encoded proteins on the iRBC surface (21).
Key among these are the P. falciparum erythrocyte membrane protein 1s (PfEMP1s) encoded by
P. falciparum var genes (21). Each parasite genome contains approximately 60 var genes that
encode antigenically distinct PfEMP1 proteins that are clonally expressed by the parasite.
PfEMP1s bind to a variety of ligands on endothelial cells and function to sequester iRBCs in the
blood vessels of various tissues, thus saving iRBCs from entering the spleen, where they would be
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
Figure 1
The Plasmodium life cycle in humans includes the asymptomatic liver stage; the blood stage, which causes disease; and the sexual
gametocyte blood stage, which infects mosquitoes that transmit the parasite. Infection begins when a female Anopheles mosquito injects
saliva that contains sporozoites into the skin and blood as it takes a blood meal (a). At this point, the infection is clinically silent, and
there is no evidence for naturally acquired immunity. However, experimental infection with attenuated sporozoites has been shown to
induce sterilizing immunity, and in this case the only known immune effectors that can reduce or block sporozoites in the skin are
antibodies. In mouse models, sporozoites enter draining lymph nodes from the skin, where they are presented by dendritic cells and
prime CD8+ T cells. The highly motile sporozoites migrate to the liver, transverse Kupffer cells, and invade a small number of
hepatocytes (b). In humans, the infection continues to be clinically silent at the liver stage, and sterilizing immunity is not naturally
acquired. However, in humans and in mice, immunization with attenuated sporozoites induces sterilizing immunity that appears to rely
on adaptive CD8+ and CD4+ T cells; on the innate production of inducible nitric oxide synthase (iNOS) and nitric oxide (NO); and on
natural killer (NK) cells, NKT cells, and γδT cells. Each sporozoite-infected hepatocyte gives rise to tens of thousands of asexual
parasites called merozoites (c). Approximately one week after hepatocyte invasion, merozoites exit the liver into the bloodstream and
begin a 48-h cycle (d ) of red blood cell (RBC) invasion, replication, RBC rupture, and merozoite release (e). Clinical symptoms of
malaria occur only during the blood stage and can begin as early as three days after the release of merozoites from the liver. Inside
RBCs, the parasite dramatically remodels the RBC, a process that involves exporting variant surface antigens (VSAs) such as
P. falciparum membrane protein 1s (PfEMP1s) to the RBC surface. VSAs act as receptors for a variety of endothelial cell ligands and
mediate binding of infected RBCs (iRBCs) to the microvascular endothelium of various organs ( f ), allowing parasites to avoid splenic
clearance. However, the sequestration of iRBCs in the microvasculature promotes the inflammation and circulatory obstruction
associated with clinical syndromes of severe malaria, including cerebral malaria with iRBC sequestration in the brain and
pregnancy-associated malaria with iRBCs in the placenta ( g). VSA-mediated rosetting of iRBCs to uninfected RBCs may also
contribute to disease (h). Coincident with the rupture of iRBCs and the release of merozoites and various parasite products are
inflammation and the clinical symptoms of malaria. Both adaptive and innate immune responses are readily detected. The key immune
effector at this stage is antibody. CD4+ cytokine-producing T cells also play a role as do NK, NKT, and γδT cells and macrophages
through the production of NO and iNOS. A small number of blood-stage parasites differentiate into sexual gametocytes, which are
taken up by mosquitos in blood meals (i ). In the mosquito, the gametes fuse, ultimately forming sporozoites that enter the mosquito
salivary gland to complete the life cycle (see Figure 2). In the mosquito, innate immune mechanisms serve to control parasite
development. Immunization of the vertebrate host with proteins expressed by the parasite in the mosquito host results in the production
of antibodies that are taken up by the mosquito with the blood meal, block parasite development, and consequently block transmission.
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destroyed. The PfEMP1-mediated sequestration of iRBCs in tissues such as the brain and placenta
has been implicated in the pathogenesis of severe malaria in children and in pregnant women.
The life cycle of P. falciparum in the human host is completed when, in a poorly understood
process, the asexual blood-stage parasites differentiate into male and female gametocytes that are
taken up in a mosquito’s blood meal. In the mosquito midgut, male and female gametes fuse to
form ookinetes that cross the midgut epithelium and ultimately differentiate into sporozoites that
invade the mosquito’s salivary glands, completing the parasite’s life cycle in the invertebrate host.
HUMAN IMMUNITY AND MALARIA
Studying Human Immunity to Malaria
Animal models of malaria have provided and will undoubtedly continue to provide important
insights into the immunobiology of Plasmodium infection (22), but ultimately, despite obvious
experimental limitations, it is critical to investigate the immune response to Plasmodium infection
in humans. In contrast to what is typically available to researchers of other infectious diseases, the
malaria research community has access to longitudinal models of both experimental and natural
P. falciparum infection in humans (23–25). Under strictly controlled conditions, volunteers are
exposed to the bites of laboratory-reared P. falciparum–infected mosquitoes. In previously unex-
posed individuals, parasites become detectable in the blood by microscopy approximately 11 days
after infection, at which point curative antimalarial therapy is administered. Since the 1980s, more
than 1,500 volunteers have been experimentally infected with P. falciparumwithout serious adverse
events, although P. falciparum–naive volunteers often experience transient malaria symptoms such
as fever, chills, headache, and myalgias. A model of direct intravenous administration of iRBCs
in healthy volunteers has also been developed, allowing investigations of the early immunological
responses to blood-stage infections while strictly controlling the size of the blood-stage inoculum
(24). The highly controlled and predictable nature of human experimental P. falciparum infections
allows for high-resolution immunological analyses during the skin, liver, and early blood stages
of the parasite life cycle.
The study of immune responses to natural infection in individuals of all ages is also feasible
in malaria-endemic areas due in part to the patterns and intensities of P. falciparum transmission.
Transmission patterns vary across endemic areas from sporadic to seasonal to year round, depend-
ing on the temperature, rains, and mosquito breeding, and transmission intensities vary from low
to high. Investigators can take advantage of these variations to design field-based immunological
studies tailored to these transmission patterns and intensities. For example, in areas of intense
seasonal malaria, such as in much of West Africa, the intensity of transmission is so great that
every individual will predictably be exposed to hundreds of infectious mosquito bites over the
course of a transmission season. Cohorts can be enrolled during the six-month dry season, when
there is little or nomalaria transmission, and then be followed throughout the malaria season. The
predictable timing and intensity of P. falciparum transmission from year to year allow for multi-
year cohort studies in which P. falciparum infections and clinical malaria episodes can be reliably
detected through active parasitological and clinical surveillance, and relevant biospecimens can
be collected at time points before, during, and after asymptomatic and symptomatic P. falciparum
infections (25).
Importantly, such designs allow study subjects to serve as their own healthy preinfection
controls and permit two general types of questions to be addressed: (a) What immune parameters
or profiles correlate prospectively with protection from malaria? (b) How do acute and chronic
P. falciparum infections modulate the human immune response? These unique and powerful
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clinical research models, informed by experimental findings in animal studies, and in conjunction
with technological advances that enhance our ability to interrogate perturbations to the human
immune system, have the potential to rapidly improve our understanding of malaria immunity.
The Immune Response to the Skin and Liver Stages of Plasmodium Infection
In humans, the skin and liver stages of P. falciparum infection are clinically silent, as they fail
to induce significant dermal, hepatic, or systemic inflammation. Not unexpectedly, the lack of a
robust innate immune response to the skin and liver stages is associated with a correspondingly
muted induction of antibody or of CD4+ and CD8+ T cell responses to the infecting sporo-
zoites in individuals exposed to natural P. falciparum infections in endemic areas (reviewed in 26).
Accordingly, there is no convincing evidence for naturally acquired immunity capable of com-
pletely neutralizing the parasite at the skin or liver stages. Indeed, even after decades of repeated
P. falciparum exposures, adults in malaria-endemic areas are at the same risk of becoming infected
with parasites as young children (27). The cellular and molecular basis of this clinical silence and
paucity of sterilizing immunity is only poorly understood. The relatively weak innate and adaptive
immune responses to the skin and liver stages may reflect the low inoculum of parasites in the
mosquitoes’ saliva (10–100 sporozoites). The inherent immunoregulatory environment of skin
(28) and liver (29) may also be exploited by the parasite to evade immune mechanisms. Normal
skin has a particularly high proportion of regulatory T cells (Tregs) in the steady state (28), and
a meta-analysis of malaria vaccine studies suggested that Plasmodium-specific Tregs are induced
during the skin stage of infection, potentially mediating immune tolerance to sporozoites as well
as to the subsequent blood stage of infection (30). Consistent with these results are experiments
in mice that show that skin Tregs and dendritic cells (DCs) are mobilized within 30 min of sporo-
zoite inoculation and that DCs downregulate MHC class II and CD86, suggesting a tolerogenic
response (31). The immunoregulatory environment of the skin may be reinforced by chronic
immune activation or immune dysregulation because of repeated exposures to sporozoites and
liver-stage antigens (32). Plasmodium-specific mechanisms that disable innate immune defenses,
such as sporozoite-mediated disruption of Kupffer cells’ respiratory burst in the liver (33), may
also affect pre-erythrocytic immunity.
In striking contrast to the lack of pre-erythrocytic immunity in natural infection, sterilizing
immunity to Plasmodium infection can be readily induced in mice (34), nonhuman primates (35),
and humans (36) through exposure to radiation-attenuated (RA) sporozoites that are able to infect
hepatocytes but that cannot replicate in the hepatocyte and do not give rise to blood-stage in-
fections. Sterilizing immunity can also be induced by exposure to genetically attenuated parasites
(37)—which also invade hepatocytes but do not replicate to produce blood-stagemerozoites—and
by exposure to sporozoites under chloroquine antimalarial chemoprophylaxis (38). Chloroquine
kills only blood-stage parasites, and thus exposure to sporozoites under chloroquine treatment
allows full exposure to sporozoites and liver-stage parasites and only transient exposure to blood-
stage parasites. The number of RA sporozoites and the route of exposure to RA sporozoites appear
critical to inducing immunity. Early studies showed that sterilizing immunity to RA sporozoites
required the bites of over 1,000 infective mosquitoes (36). A recent vaccine trial in humans showed
that subcutaneous RA sporozoite immunization did not confer protection (39); however, intra-
venous RA sporozoite immunization in animal models (39) and humans (40) was protective in a
dose-dependent manner. Thus far, most experimental exposures to sporozoites have been shown
to be effective only when individuals are challenged with homologous sporozoites, and in endemic
areas individuals would rarely be infected with the same parasite clone given the extreme genetic
diversity (41). Even though whole sporozoite–induced sterile immunity does not have a natural
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counterpart, there is considerable interest in understanding the mechanisms underlying the dis-
cordant acquisition of immunity to experimental and natural P. falciparum infection to aid in the
development of whole sporozoite vaccines for use in humans.
In humans, RA sporozoite exposure induces antibodies and CD4+ and CD8+ T cells (40)
that react to several sporozoite and liver-stage antigens (42–44), but the relative contribution
and antigen specificity of these putative effector mechanisms remain unclear. Volunteers exposed
to sporozoites under chloroquine treatment develop complete protection against homologous
sporozoite challenge (38) that lasts at least 28 months (45). Exposure elicits both antibody and
T cell responses against sporozoite and blood-stage antigens (38), and protection has been asso-
ciated with pluripotent effector memory T cells producing interferon-γ (IFN-γ), tumor necrosis
factor (TNF), and interleukin-2 (IL-2) (38) that are most likely directed against liver rather than
blood-stage antigens (46).
Animal models have allowed detailed characterization of the immunemechanisms at play in the
skin (reviewed in 47) and in the liver (48) during Plasmodium infection thatmay provide insights for
the ongoing development of whole sporozoite–based vaccines. In mice, within minutes to hours
of RA sporozoite inoculation into the dermis, 10–25% of sporozoites reach the liver via the blood-
stream, while 15–25% enter skin-draining lymph nodes (reviewed in 47). As early as 48 h after
sporozoite inoculation, Plasmodium-specific CD8+ T cells are detectable in skin-draining lymph
nodes (49). Surgical removal of skin-draining lymph nodes or inhibition of T cell egress from these
lymph nodes significantly decreases the number of T cells reaching the liver and disrupts CD8+
T cell–mediated killing of intracellular liver-stage parasites (49) that involves both cytolytic (i.e.,
perforin/granzyme) and noncytolytic (i.e., IFN-γ-induced nitrous oxide) pathways (reviewed in
50, 51). A key question is: How are CD8+ T cells primed to sporozoite antigens? Recent stud-
ies using parasites carrying a mutant circumsporozoite protein containing the ovalbumin-derived
SIINFEKL epitope and a variety of mouse mutants showed that DCs phagocytose sporozoite
antigen and cross-present parasite-derived peptides on MHC class I to CD8+ T cells (52). Ac-
cordingly, in vivo depletion of CD11c+ DCs abrogates priming of Plasmodium-specific CD8+ T
cells (53). Antigen presentation may not be limited to DCs, as sporozoites traverse Kupffer cells
in the liver prior to hepatocyte invasion and shed parasite proteins into the cell cytoplasm that
may also be presented to CD8+ T cells (52). Surprisingly, to date only a few T cell antigenic
peptides derived from sporozoites have been identified. Recent studies using liver-stage-specific
epitope profiling have revealed three new CD8+ T cell epitopes for the mouse Plasmodium species
(54, 55). Clearly, additional approaches are needed to identify T cell epitopes to allow better
characterization of protective and nonprotective T cell responses.
Concerning the length of time required to primeT cells, we find it is interesting that sporozoite
molecules may be retained in skin-draining lymph nodes as well as in the spleen and liver for up to
two months after exposure to RA sporozoites or infected mosquito bites (56). Although previous
studies suggested that CD8+ T cell priming only requires short (<24 h) exposure to antigen (57),
prolonged antigen exposuremight be required to optimize the liver-stage-specificCD8+ Tcell re-
sponse by maximizing the expansion of effector cell populations (56). Indeed, high levels of CD8+
T cells are required to kill intrahepatic parasites (58), and similarly in humans, the magnitude of
vaccine-induced CD8+ T cell responses specific for pre-erythrocytic antigens is correlated with
protection (59). Only one infected hepatocyte escaping the cytotoxic T cell response might be
enough to initiate a blood-stage infection. This is a likely reason why extremely high frequencies
of memory CD8+ T cells are required to induce sterile immunity after immunization with irra-
diated sporozoites (58). RA sporozoite–induced antibodies have also been implicated as effectors
in pre-erythrocytic immunity in mice (reviewed in 60) through enhancing sporozoite clearance,
decreasing sporozoite motility (61), or blocking hepatocyte invasion (62). Undoubtedly, animal
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models will continue to inform further investigations that also take advantage of recent advances
in human skin immunobiology (63) and humanized mouse liver models (64).
The early observation of RA sporozoite–induced protection from Plasmodium infection (65)
spurred the pursuit not only of whole sporozoite–based vaccines but also of sporozoite protein
subunit vaccines as well. The most advanced candidate in this regard is RTS,S, a subunit vaccine
that targets circumsporozoite protein, a surface protein on sporozoites that is critical for hepa-
tocyte invasion (reviewed in 66). RTS,S induces both antibodies and CD4+ T cells (not CD8+
T cells), but unambiguous correlates of protection have yet to be identified (67). Remarkably,
RTS,S vaccination reliably confers sterile protection in ∼50% of malaria-naive adults (66).
However, in African infants and children the protective efficacy of RTS,S is 30–50% against
clinical malaria (9, 68), whereas durable protection from infection per se is not observed. Similarly,
a vaccine targeting the liver-stage antigen thrombospondin-related adhesion protein (TRAP)
that relies on the generation of CD8+ T cell immunity showed partial efficacy in malaria-naive
adults in Europe (59) but not in children (69) or adults residing in malaria-endemic regions of
Africa (70).
The question that emerges from these observations is why malaria vaccine candidates that
target the sporozoite or liver stage appear to be more effective in naive adults than in the
target populations, namely African children. There are several possible explanations, but no real
answers. The malaria-naive subjects are drawn primarily from Europe and the United States and
may have important genetic differences, most notably in the MHC HLA alleles (71) and other
immune-related genes, including the innate system’s Toll-like receptors (TLRs). Coinfections
with other pathogens are common in malaria-endemic areas, and these may modulate the
development of Plasmodium-specific immunity (72). In addition, the nutritional status (73) and
composition of gut microbiota in African children (74) may have profound immunomodulatory
effects on host immunity to malaria, particularly the immune microenvironment in the liver (75),
which drains portal blood.
Given the increased focus on vaccines that target the sporozoite and liver stage of infection for
the purpose of eradication, studies are badly needed that will identify the mechanisms underlying
refractoriness to the natural acquisition of sterile immunity and vaccine failures in endemic areas.
Such studies will benefit from the development of several new tools. Antigen-specific MHC class
I and class II tetramers would help define the extent to which P. falciparum–specific T cells are
engaged and function in individuals in endemic areas compared with sporozoite-exposed naive
individuals. Biomarkers reflective of the liver-stage parasite burden would disentangle the relative
contributions of effective liver-stage immunity and early blood-stage immunity; they would also
allow the immune mechanism at play in each to be better understood.
The Response to Blood-Stage Infection
The clinical manifestations of malaria are caused by asexual blood-stage parasites as they replicate
in the blood (Figure 1). Although complex and incompletely understood (6), malaria pathogen-
esis is generally thought to be driven by two distinct processes: sequestration and inflammation.
Sequestration involves the binding of iRBCs to receptors on the vascular endothelium via specific
parasite-host interactions, causing microvascular obstruction, local ischemia, and inflammation
in the brain and other vital organs (76, 77). P. falciparum also induces a systemic inflammatory
response akin to bacterial sepsis (78), which may exacerbate iRBC sequestration by upregulating
vascular adhesion molecules such as ICAM-1 (79). The question of whether inflammation or se-
questration is the central initiating event in malaria pathogenesis is a matter of ongoing debate
(80, 81), but it seems likely that these processes occur in parallel and are mutually reinforcing.
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In areas of intense P. falciparum transmission, resistance to severe life-threatening malaria
(discussed below) is generally acquired by the age of five years, whereas children remain susceptible
to repeated bouts of febrile malaria throughout adolescence, eventually achieving near complete
clinical immunity to blood-stage parasites by adulthood (3). Here we focus on two immunological
processes that play crucial roles in controlling P. falciparum blood-stage parasites and the disease
they cause: inflammation and its regulation, and the antibody response.
In previously unexposed individuals, blood-stage P. falciparum parasites invariably induce fever
and other signs and symptoms of malaria (82), a process driven by the production of proin-
flammatory cytokines and chemokines such as IL-1β, IL-6, IL-8, IL-12(p70), IFN-γ, and TNF
(83–85). Recent work has begun to identify the P. falciparum pathogen-associated molecular pat-
tern (PAMP) molecules that trigger inflammation through pattern-recognition receptors (PRRs)
expressed by immune cells. These PAMPs include GPI anchors (TLR2) (86), hemozoin (NLRP3
inflammasome) (87), CpG-containing DNA motifs bound to hemozoin (TLR9) (88), and AT-
rich DNA motifs (unidentified cytosolic receptor) (89). A handful of Plasmodium proteins have
also been identified as drivers of inflammation through specific interactions with host receptors.
For example, particular PfEMP1s have been recently implicated in parasite sequestration in brain
endothelium in severe cerebral malaria in children (90–92). The receptor for these PfEMP1s
was identified as the endothelial protein C receptor (EPCR) that mediates cytoprotective effects
through activated protein C, suggesting that PfEMP1 binding to EPCR may block its protective
function and contribute to the pathology of cerebral malaria (77). Merozoite surface protein 1
(MSP1) that is shed from the merozoite surface as the parasite invades RBCs was shown to bind
to S100P—a member of the proinflammatory S100 protein family—and to block S100P activity
(93). These studies were recently extended to show that MSP1 binds to all S100 family mem-
bers (M. Waisberg, unpublished observation). An area that requires further study is the extent
to which heterogeneity in the host inflammatory response and disease severity are the result of
(a) polymorphisms in these and other Plasmodium proteins; (b) the expression of specific subsets
of PfEMP1s; or (c) variability in the structure, configuration, or quantity of Plasmodium PAMPs.
Work in animal models demonstrates a role for various innate immune cells in sensing early
blood-stage infection, promoting inflammation, inhibiting parasite growth, and shaping adaptive
immune responses (reviewed in 94) including monocytes/macrophages (95), mast cells (96), neu-
trophils (97), natural killer (NK) cells, NKT cells, and γδ T cells (98). Human NK cells appear
to be a particularly important early source of IFN-γ in response to iRBCs in vitro, a central cy-
tokine in the immune response to malaria that promotes the destruction of iRBCs by activated
macrophages. In humans, γδ T cells contribute to early IFN-γ production to a lesser degree,
whereas later IFN-γ production is dominated by αβ T cells (99).
On the one hand, Plasmodium-induced inflammation likely plays an important role in the
early control of parasite replication; for example, IFN-γ and TNF kill blood-stage P. falciparum
parasites through the induction of nitric oxide (NO) and other toxic radicals (100). On the other
hand, excessive inflammation has been linked to severe and fatal malaria (101), which occurs in a
minority of individualswhohave little or nopriormalaria exposure (16).However, in endemic areas
where individuals are repeatedly infected, blood-stage infections commonly cause a mild febrile
illness or no symptoms at all (3), consistent with the long-standing hypothesis that tolerance to
Plasmodium-induced inflammation can develop (102). This notion is supported by early studies in
humans showing that the risk of fever decreases with serial experimental Plasmodium infections
(82) and thatPlasmodium infection induces cross-tolerance to endotoxin (103). Consistent with this
hypothesis,mousemodels of nonlethalmalaria show thatPlasmodium-induced inflammation (TNF
and IFN-γ) peaks 5–10 days after infection (104, 105) and then diminishes owing to the production
of the regulatory cytokines TGF-β (104) and IL-10 (105) even before parasitemia decreases. In
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humans, cross-sectional studies show that higher ratios of pro- to anti-inflammatory cytokines in
serum during acute malaria are associated with more severe disease (83, 106), although this is not
a consistent finding (107). What remains unknown are (a) whether malaria-induced inflammation
is attenuated within individuals as they are repeatedly reexposed to P. falciparum infections in
endemic areas and (b) the extent to which this contributes to clinical immunity (108). Also unclear
are the immunoregulatory mechanisms and cells that mediate control of P. falciparum–induced
inflammation in humans (109, 110) and the longevity of regulatory responses in the absence of
ongoing P. falciparum exposure.
A longitudinal study of children in Mali (P.D. Crompton, unpublished data) provides some
insight into these questions. A systems biology approach (25) was used to analyze leukocytes
sampled from children before the malaria season and seven days after treatment of their first
febrile malaria episode of the ensuing season when symptoms had resolved. Leukocytes were
stimulated with iRBC lysates in vitro, and various immune parameters were measured. This anal-
ysis revealed that before the malaria season the children’s immune cells responded to the iRBC
lysates by producing proinflammatory mediators such as IL-1β, IL-6, and IL-8. Following febrile
malaria, there was a marked shift in the response to iRBCs, with the same children’s immune
cells producing lower levels of proinflammatory cytokines and higher levels of anti-inflammatory
cytokines (IL-10, TGF-β). In addition, molecules involved in phagocytosis-mediated killing and
activation of adaptive immunity were upregulated after febrile malaria as compared to before.
This shift was accompanied by a marked increase in P. falciparum–specific CD4+Foxp3− T cells
that coproduced IL-10, IFN-γ, and TNF; however, P. falciparum–inducible IL-10 production
remained upregulated only in children with persistent asymptomatic infection. These findings
suggest that in the face of P. falciparum reexposure, children rapidly acquire exposure-dependent
P. falciparum–specific immunoregulatory responses that dampen potentially pathogenic inflam-
mation while enhancing antiparasite effector mechanisms that control parasite replication. These
data provide mechanistic insight into the observation that P. falciparum–infected children in en-
demic areas commonly experience a mild febrile illness or no symptoms at all and often keep
parasite numbers in the blood in check (112, 113).
Until recently, the cellular source of IL-10 in P. falciparum–infected individuals was un-
clear (109). The finding in Mali that CD4+Foxp3− Th1 cells are the major source of IL-10
(P.D. Crompton, unpublished data) corroborates a cross-sectional study in the Gambia in which
FOXP3−CD45RO+CD4+ Tcells, rather thanTregs, were identified as the only substantial source
of IL-10 in children with malaria (107). As in Mali, this same study showed that a significant pro-
portion of IL-10-producing CD4+ T cells coproduced IFN-γ, and this cell population was signif-
icantly increased in children with mild versus severe malaria (107). Similar self-regulating CD4+
Th1 cells (114) have been observed in other infections in humans (115, 116) and animal models
(117, 118), pointing toward a protective role for this cell population.The ability to control excessive
P. falciparum–induced inflammation in early life may be the key adaptation that confers protection
from potentially life-threatening disease in young children who have yet to acquire protective
antibodies, which are only reliably acquired after many years of P. falciparum exposure (119).
In 1961, Cohen et al. (120) established that antibodies play a central role in blood-stage malaria
immunity by showing that the transfer of purified IgG from malaria-immune adults to children
with acute malaria led to rapid and profound reductions in parasite numbers in the blood and
resolution of fever. Over 50 years later, we have yet to fully understand which of the more than
5,000 P. falciparum proteins (17) are targets of protective antibodies, the precise mechanisms by
which these antibodies protect, and why they are only acquired after years of repeated infections—
all critically important questions for blood-stage malaria vaccine development, an effort that so
far has been largely empiric and unsuccessful (121). Progress toward addressing these questions
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has been catalyzed in recent years by advances in basic B cell biology and by the development of
new tools to probe B cell responses to Plasmodium infection.
The inefficient acquisition of antibodies that protect against malaria has been attributed in part
to the genetic diversity of many P. falciparum proteins (122) and the parasite’s ability to clonally
vary the proteins it expresses on the surface of iRBCs (123), such that it may take years living in an
endemic area for an individual to be exposed to a sufficient number of parasite clones to generate a
protective repertoire of antibodies. This highly successful immune evasion strategy may underpin
the limited efficacy of blood-stage vaccines that have targeted polymorphic merozoite proteins
(124). To be successful going forward, blood-stage vaccines will likely need to induce antibodies
specific either for conserved proteins that are critical to parasite survival or for a large repertoire
of clonally variant antigens expressed on the surface of iRBCs, such as the PfEMP1 family.
Hope for the former possibility was recently bolstered by the discovery of the P. falciparum
reticulocyte-binding protein homologue 5 (PfRH5), a conserved protein that is essential formero-
zoite invasion of erythrocytes (125–127). Moreover, antibodies raised in animals against either
PfRH5 (128, 130) or its erythrocyte receptor, basigin (127), inhibit parasite invasion of erythro-
cytes in vitro. Although PfRH5 appears to be a relatively poor immunogen in the context of
natural P. falciparum infection (128, 129) (possibly explaining why it is more conserved than other
merozoite proteins), naturally acquired antibodies specific for PfRH5 correlate with protection
from malaria in longitudinal studies in Papua New Guinea (131) and in Mali (129). Additionally,
PfRH5-specific IgG purified from malaria-experienced adults inhibits the growth of homologous
and heterologous P. falciparum parasites in vitro (129, 132). In principle, if immunization with
PfRH5 reliably blocks merozoite invasion of RBCs, it would not only prevent disease but may
also disrupt the parasite’s life cycle and prevent transmission to mosquitos.
The development of a vaccine that would confer protection against malaria by inducing im-
munity to clonally variant P. falciparum antigens is a formidable challenge. However, evidence
from studies in malaria-endemic areas suggests that the clonally variant PfEMP1 family is a ma-
jor target of humoral immunity to malaria (133) and that repeated P. falciparum infections may
elicit a protective repertoire of PfEMP1-specific antibodies (134). How might this immunity be
replicated through vaccination? One approach may be to immunize with whole killed blood-stage
parasites that have been genetically modified to express the entire PfEMP1 repertoire of a given
parasite simultaneously (135). This approach could complement ongoing efforts to develop killed
or attenuated whole-parasite blood-stage vaccines (136), which intriguingly appear to mediate
protection through CD4+ T cells, IFN-γ, and NO rather than through antibodies (137).
There ismounting evidence that, in addition to using genetic polymorphism and antigenic vari-
ation to evade immune responses, Plasmodium evades humoral immunity through dysregulation
of CD4+ T cell and B cell function. It is well established that long-lived protective antibody re-
sponses depend on the generation ofmemory B cells (MBCs) and long-lived plasma cells (LLPCs),
a process that relies on CD4+ T cell help (138). Although there is heterogeneity in the magnitude,
quality, and longevity of antibody responses following infection or vaccination, in general anti-
body responses are long-lived, even after one or a few exposures (139). For instance, the estimated
half-life of the IgG response to the measles vaccine is>300 years (139). In contrast, several studies
have reported that P. falciparum–specific antibodies decline to undetectable or nearly undetectable
levels within 3–9 months of documented malaria episodes in children (reviewed in 119). A study
using protein arrays corroborated and extended this finding by showing that children generate
IgGs specific for hundreds of P. falciparum antigens in response to a single malaria season but
rapidly lose most of what they gain during the subsequent six-month dry season, a period of
little or no malaria transmission (140), suggesting that in children this response is dominated
by short-lived plasma cells rather than LLPCs. The same study showed that with each year of
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P. falciparum exposure, the level of P. falciparum–specific IgG persisting through the dry season
increases incrementally until young adulthood, when IgG levels are maintained at high levels (cor-
responding temporally with the acquisition of malaria immunity) and fluctuate less in response to
P. falciparum infection. These data suggest that the gradual acquisition of clinical immunity to
malaria may reflect the need for repeated infections to fill the P. falciparum–specific LLPC com-
partment to the point where steady-state antibody levels exceed a protective threshold.
On the basis of anecdotal reports of waning immunity in the absence of P. falciparum exposure
as well as of inconsistent antibody boosting upon reinfection (141), even to conserved antigens
(142), investigators have long suspected that malaria might not generate MBCs. However, several
studies have now shown that P. falciparum–specific MBCs are generated in response to infection,
albeit inefficiently, as their prevalence appears to be relatively low among adults (∼30–50%) (143–
147), even those with a history of documented P. falciparum infections. Once acquired, however,
MBCs appear to be long-lived (145, 146) and may persist longer than antibodies in the absence of
ongoing P. falciparum exposure (146, 148). The findings for P. falciparum–induced MBCs stand in
contrast to studies that show, for example, that smallpox vaccine–specificMBCs are generated and
persist in nearly all vaccinees for ≥50 years in the absence of antigen reexposure (149). Therefore,
it appears that P. falciparum infection can generate long-lived MBCs but less efficiently, at least
compared with vaccines for other pathogens.
The relatively inefficient acquisition of P. falciparum–specific LLPCs and MBCs may be re-
lated to dysregulated B cell antigen–driven differentiation. Altered B cell function is well described
in other infections; for example, HIV and hepatitis C virus infection are associated with an in-
crease in CD19+CD20+CD21−CD27−CD10− and Fc receptor-like-4+ B cells (150, 151). In
HIV-infected individuals, these cells are hyporesponsive or exhausted and may contribute to the
humoral deficiencies associated with HIV (150). An increase in a phenotypically similar subset
of B cells has been observed in malaria-exposed children and adults across genetically and geo-
graphically diverse populations (reviewed in 119). In the context of malaria, this B cell subset is
referred to as atypical (152) rather than exhausted because the function of these cells and whether
they are beneficial or detrimental in malaria remain unclear. That P. falciparum per se may drive
this response has been suggested by the observation of differential expansion of atypical MBCs
in age-matched children living under similar conditions in rural Kenya, with the exception of
P. falciparum exposure (153). Intriguingly, at the single-cell level, P. falciparum exposure has re-
cently been associated with the acquisition of atypical MBCs that differed in their Ig gene reper-
toire from classicalMBCs, suggesting that these two populations develop fromdifferent precursors
(154).
Malaria may also dysregulate helper CD4+ T cell responses. PD-1, a marker of T cell
exhaustion, is upregulated on CD4+ T cells in children following P. falciparum infection (155).
Although the functional significance of this observation in humans is unclear, Butler et al.
(155) reported that P. yoelii infection in mice induces phenotypic and functional CD4+ T
cell exhaustion. Furthermore, in vivo blockade of the PD-1 ligand PD-L1 and the inhibitory
receptor LAG-3 restored CD4+ T cell function, augmented the number of T follicular helper
and germinal center B cells, increased antibody levels, and ultimately enhanced the clearance of
blood-stage parasites (155).
Malaria-associated B cell dysregulation may be driven by direct interactions between
P. falciparum products and B cells. For example, the cysteine-rich interdomain region 1α of
PfEMP1 has been implicated as a T cell–independent polyclonal B cell activator and Ig-binding
protein (156). There is also evidence that systemic mediators of B cell differentiation and survival
such as BAFF are modulated during P. falciparum infection (157, 158). Moreover, chronic expo-
sure to P. falciparum PAMPs could result in tolerance of PRRs expressed on B cells and DCs,
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which play critical roles in enhancing B cell responses. Indeed, recent clinical trials show that the
TLR9 agonist CpG enhances the IgG and MBC response to blood-stage vaccine candidates in
malaria-naive adults (159) but not in adults chronically exposed to P. falciparum (160). Further
studies are needed to define how P. falciparum exposure modulates PRR function and how this
might influence homologous and heterologous LLPC and MBC responses.
The Immune Response in Severe Malaria
Each year there are approximately 225million cases of malaria in Africa, most of which are uncom-
plicated and are resolved with time even without treatment with antimalarial drugs. However, in a
small portion of cases—approximately 1%, almost exclusively young children or older individuals
with little or no prior exposure—the infection becomes severe and life threatening, resulting in
nearly one million deaths each year (1). Malaria during pregnancy can also be severe, resulting
in substantial maternal, fetal, and infant morbidity. We focus our discussion on severe malaria in
young children and refer the reader to an excellent review on immunity to malaria in pregnancy
(161).
Most severe malaria deaths in children are due to three overlapping clinical syndromes:
(a) malaria with impaired consciousness (cerebral malaria), (b) malaria with respiratory distress
due to severe metabolic acidosis, and (c) severe anemia (162). Although the pathophysiology is
incompletely understood, severe cerebral malaria, one of the most deadly forms of severe malaria,
is associated with ischemia caused by sequestration of iRBCs in the brain and microvascular dam-
age, edema, blood-brain barrier breakdown, and immune cell activation and recruitment resulting
in inflammation and oxidative stress (reviewed in 163, 164). Indeed, in children the pathology
of severe disease has been consistently linked to excessive inflammatory responses including the
production of the proinflammatory cytokines TNF-α, INF-γ, IL-1β, and IL-6 and a linked re-
duced production of the anti-inflammatory cytokine IL-10. We do not have a clear picture of the
sequence of events responsible for the progression from uncomplicated malaria to severe disease
or of the events that trigger severe disease. Currently, it is not possible to distinguish children who
are at high risk to progress from uncomplicated to severe malaria and we have no specific therapies
that are effective for children who present with severe disease. Clearly, a better understanding of
the immune mechanisms at play in severe disease would contribute to efforts at developing such
diagnostics and therapies.
It is not clear how resistance to severe disease is acquired or if the protective immune mech-
anisms at play in uncomplicated and severe disease are similar. That immunity to severe malaria
is not the same as immunity to uncomplicated malaria is suggested by the observation that young
children who survive an episode of noncerebral severe malaria appear to have life-long immunity
to severe malaria but remain susceptible to uncomplicated malaria until adolescence (2). Children
who develop severe disease may be relatively naive to malaria, having little exposure early in life.
This begs the question: How many malaria infections are necessary to achieve protection from
severe disease? The answer is not clear, as determining the risk of severe malaria in relation-
ship to infections requires large cohorts to capture the relatively rare cases of severe disease, and
such studies have simply not been done. However, a recent nested case control study in Kenya
provided evidence that children who suffer severe malaria do not have fewer infections early in
life compared with community controls (165). Cerebral malaria is rare in very young children in
areas of high year-round transmission, suggesting that immunity to cerebral malaria is acquired
early under the cover of passively acquired maternal antibodies (166). It is also possible that the
mechanisms underlying protection may be more complicated and relate to the brain physiology
of young children and their ability to mount an inflammatory response. Based on models of the
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relationship between exposure to infection and resistance to severe disease, investigators have pro-
posed that resistance to noncerebral severe malaria occurs after only a few infections—even after
a single infection in children protected by maternal antibodies (167). If so, then the acquisition
of immunity to uncomplicated disease and the acquisition of immunity to severe disease are quite
different or at the very least occur over very different timescales.
Are there genetic factors known to be protective in severe disease? Is susceptibility to severe
disease in children due to inborn errors in immunity leading to failure to control inflammation?
Researchers have proposed that in populations widely exposed to pathogens from birth, including
malaria, life-threatening diseases in children, such as severe malaria, result from collections of
single-gene variants affecting immunity to primary infection (168). Indeed, Casanova and col-
leagues (168) modeled malaria mortality with age for simple Mendelian inheritance of genetic
susceptibility and concluded that a few dozen gene variants could account for the human genetic
contribution to severe malaria. A question remains: What are these genes? Although malaria has
been recognized as having a strong impact on the human genome, the full impact of human
genetics on resistance to severe disease remains largely unexplored (15). Linkage studies have
provided evidence for a variety of genes, including HbS and other hemoglobin variants, that in-
fluence malaria severity, many of which likely affect the RBC functions necessary for parasite
invasion or sequestration of iRBCs, not immunity per se. In addition, numerous immune sys-
tem genes show association with resistance or susceptibility to malaria, including those encoding
MHCmolecules, FcγRIIB, components of both the type I and type II IFN responses, IL-12, and
NO synthase (NOS) (15). However, few of these associations have been tested in more than one
endemic setting, and when tested results have varied.
The sequencing of the human genome in 2003 allowed genome-wide association (GWA)
studies for severe malaria. The first GWA study of severe malaria carried out in the Gambia
identified only HbS to be associated with resistance (169), even though HbS accounts for only
approximately 8–10% of resistance. The second GWA study of severe malaria carried out in
Ghana identified two novel resistance loci—a RBC calcium pump (ATP2B4) and an endothelial
tight junction protein (MARVELD3) (170)—and confirmedHbS and blood groupOas protective.
Thus, for malaria, many resistance genes remain to be discovered.
It is reasonable to assume that features of the infecting parasite also contribute to severe
disease, analogous to virulence factors in other pathogens. However, thus far only a few such
features have been identified. The overall total parasite burden in children with uncomplicated
malaria as measured by the concentration of the malaria-produced histidine rich protein 2 in the
plasma predicts progression to severe disease, but the factors that determine parasite loads are not
known (171). In terms of particular parasite gene products that contribute to severe disease, only
the PfEMP1s have been identified. Placental malaria in pregnant women is caused by parasites
that express one particular PfEMP1, var2CSA, that enables them to sequester in the placenta,
where the var2CSA ligand chondroitin sulfate A (CSA) is selectively expressed, causing damage
to the placenta, fetus, and mother (172). In addition, one particular PfEMP1 that binds to EPCR
is associated with cerebral malaria (90, 173, 174), and brain autopsies of Malawian children who
died of cerebral malaria show loss of EPCR at sites of sequestered iRBCs (77).
Because severe disease is difficult to study in children, most investigations of the cellular and
molecular basis of severemalaria have been restricted tomousemodels, in particular amousemodel
of cerebral malaria. At present, the model’s value to understanding cerebral disease in children
is controversial (175). Nonetheless, the hope is that studies in mice will provide clues about the
immune mechanisms underlying the disease that can contribute to the development of adjunctive
therapies in cerebral disease in children. In the best-studied model, infection with the mouse-
adapted parasite P. berghei ANKA results in rapid death of susceptible C57BL/6 mice within six to
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eight days. As for the human disease, the pathogenesis of cerebral malaria inmice appears to be due
to a combination of parasite sequestration in the brain and parasite-induced hyperinflammation
(reviewed in 163). However, the order and importance of events leading to mouse cerebral malaria
are still incompletely understood, and sequestration of iRBCs and hyperinflammation are not
sufficient to explain completely the pathogenesis of cerebral malaria in mice (176). Inflammatory
responses are required for the development of cerebral malaria, and both adaptive and innate
immune cells appear to play critical roles in the inflammatory process. For example, the depletionof
CD4+ and CD8+ T cells is protective against cerebral malaria (177), as is depletion of neutrophils
(178); however, the mechanisms by which these contribute to severe disease is not completely
understood. Recently, malaria antigen–specific CD8+ T cells recognizing peptides derived from
Plasmodium glideosome-associated protein 50 (GAP50) were shown to expand during infection in
mice, migrate to the brain, and damage the blood-brain barrier upon recognizing GAP50 peptides
cross-presented by brain endothelial cells (179), suggesting that the first event in cerebral malaria
may be the activation and recruitment of CD8+ T cells by parasite antigens. Other immune cells
in the brain are activated during cerebral malaria and play distinct roles in the pathogenesis. For
example, brain macrophage activation precedes CD8+ T cell accumulation and proliferation in
cerebral malaria (180). Clearly, we need to better understand the cellular and molecular basis of
severe malaria to facilitate the development of adjunctive therapies.
The mouse model of cerebral disease has allowed for an analysis of genes that modulate severe
disease. Genetic deficiencies have been described that confer resistance to cerebral malaria in-
cluding, among many others, ones that affect PAMP detection (181–183), inflammatory cytokine
production (184, 185), and leukocyte adhesion (186). One particularly interesting class of genes
that function as resistance factors in mouse cerebral malaria are those that function as suscep-
tibility genes in mouse models of the autoimmune disease systemic lupus erythematosus (SLE).
SLE is interesting in the context of malaria immunity because in humans SLE is six to eight times
more common in African American women compared with women of European descent (187),
suggesting that the African genome contains SLE susceptibility genes. Such genes may have been
selected for their protective effect in severe malaria, although thus far SLE susceptibility genes
have not been identified in the African genome.Two SLE-susceptiblemouse strains develop lethal
autoimmune disease by six months of age: One strain is deficient in Fcγ receptor II B (FcγRIIB)
(188), an inhibitory receptor that can serve to control inflammation, and the other strain has mul-
tiple copies of the gene encoding TLR7tg (189), the intracellular receptor for RNA. Remarkably,
these two mouse strains when infected at four to six weeks of age, before the development of
any symptoms of autoimmune disease, were completely protected against cerebral malaria (181)
despite the fact that parasitemia developed equivalently to that in wild-type mice. The effect of
FcγRIIB deficiency was of particular interest because a human loss-of-function polymorphism of
FcγRIIB is more frequent in Africans (190, 191) and associated with SLE risk in Asia (192). The
immune parameter that best explained the ability of the SLE-susceptible mice to resist cerebral
disease was their production of large quantities of the anti-inflammatory cytokine IL-10 (181).
This observation is reminiscent of the finding that malaria in Malian children induced a switch
from pro- to anti-inflammatory responses with IL-10 predominating. We hypothesize that early
in life, as the effect of the autoimmune susceptibility genes begins to manifest in inflammation, the
immune system counters with an anti-inflammatory response that confers the protection to cere-
bral malaria that we observed. This inflammatory–anti-inflammatory response may teeter-totter
back and forth with age, with inflammation inevitably winning out.
If the African genome contains SLE susceptibility genes, then we would expect a prevalence of
autoimmune disease. Paradoxically, autoimmune disease is strikingly absent frommalaria-endemic
areas of Africa (193), leading Greenwood and colleagues (194) to speculate that malaria suppresses
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autoimmunity. Evidence for their hypothesis was first provided by experiments showing infection
of autoimmune-susceptible NZB and (NZB × NZW) F1mice with nonlethal parasites protected
from autoimmune disease (195). The effect of malaria infections on autoimmune disease does not
appear to be unique, given that infection with gammaherpesvirus also seems to protect against
SLE (196). One possible explanation for these observations is that infections such as malaria
induce inflammatory responses that provoke anti-inflammatory responses that are protective in
autoimmune disease. Outside of the African pathogen environment, such as in the United States,
unchecked SLE susceptibility genes lead to SLE. Thus, we speculate that severe disease in African
children may be the result of a combination of inborn errors in key components of the immune
control of inflammation and the child’s exposure to pathogens that have the ability to induce
anti-inflammatory immune responses.
MOSQUITO IMMUNITY AND MALARIA
The lack of adaptive immunity in insects, the relatively simple organization of insect immune
systems, and the ability to disrupt gene function in adult stages make insects powerful models
for understanding the basic molecular mechanisms that mediate innate immune responses (197).
This is particularly true of anopheline mosquitoes, the natural vector of malaria, as models of
antiplasmodial responses. Understanding the interactions of the mosquito immune system that
affect Plasmodium parasites is critical for elucidating the factors that sustain transmission in the
field, but it can also provide new insights into molecular mechanisms that may operate in the
human host.
Epithelial Responses to the Gut Microbiota and Plasmodium Infection
Mosquitoes become infectedwhen they ingest blood from a host that containsPlasmodium gameto-
cytes (Figure 2). Fertilization takes place in the lumen of themidgut, and the parasite matures into
a motile form, the ookinete, in the complex environment of a blood meal undergoing digestion,
at a time when the gut microbiota is proliferating. Epithelial cells need to protect the host from
pathogenic organisms, but they must do so without mounting immune responses against the nor-
mal flora. Recent studies have found that an immune-modulatory peroxidase (IMPer) is secreted
by midgut cells of A. gambiae and, together with dual oxidase (Duox), catalyzes the formation of a
dityrosine network on the luminal surface of midgut epithelial cells (198). This network prevents
activation of gut immune responses by immune elicitors from commensal microbes. The dityro-
sine network also enhances Plasmodium parasite transmission because it allows parasites to develop
in the midgut lumen without activating NOS expression. Disruption of this barrier by silencing
either IMPer or Duox results in strong and effective pathogen-specific immune responses (199).
Innate Immune Memory Response to PlasmodiumMidgut Invasion
The innate immune system has an ancestral origin and has been thought to be hard-wired and
unable to adapt to the environment. Insects lack adaptive immunity and rely on the innate im-
mune system to mount defense responses against pathogenic organisms. However, memory-like
responses have been described in several insects, a phenomenon that has been termed immune
priming (200, 201). Although these studies challenge the dogma that invertebrates lack the ability
to mount adaptive responses, a functional mechanism that would allow the innate immune system
to remember a pathogen remained elusive. Recent studies also revealed that NK cells, central
players of the vertebrate innate immune system, are capable of intrinsic immunological memory
(202–204), but the mechanism(s) mediating these responses remain to be defined.












































































































Mosquitoes become infected when they ingest gametocytes (a) that transform into mature gametes in the midgut lumen
(b). Fertilization takes place, giving rise to a zygote (c) that matures into an ookinete, a motile stage that invades the mosquito midgut
(d ). Ookinetes transform into oocysts (e) when they reach the midgut basal lamina and begin to divide continuously, generating
thousands of sporozoites that are released into the mosquito circulatory system ( f ), invade the salivary glands ( g), and are injected into
a new host when the mosquito takes a second blood meal (h). (Inset) When ookinetes invade the midgut, they disrupt the barriers, such
as the peritrophic matrix (blue line in inset), that prevent direct contact between the gut microbiota and epithelial cells and inflict damage
on the invaded midgut cell. Midgut invasion triggers the release of a hemocyte differentiation factor that increases the number of
circulating phagocytic cells called granulocytes ( green cells). This priming enhances the immune response to subsequent Plasmodium
infections.
A recent study in A. gambiae mosquitoes revealed that a strong priming response is established
when Plasmodium ookinetes breach the natural gut barriers and along with bacteria come in close
contact with invaded epithelial midgut cells (205). Themosquito’s immune system learns from this
exposure and establishes a systemic state of enhanced immune surveillance. Upon reexposure to
a similar insult, the immune system mounts a more effective antibacterial response that indirectly
harms Plasmodium parasites through a bystander effect. What the immune system remembers is
the interaction between parasite-invaded midgut cells and bacteria (205).
Immune priming was found to be mediated by a hemocyte differentiation response that per-
sists for the life span of the mosquito (205). Exposure to Plasmodium/bacteria infection increased
the proportion of circulating granulocytes—macrophage-like phagocytic cells—and triggered a
differentiation process that altered the morphology and binding properties of these cells. Follow-
ing priming, a hemocyte differentiation factor (HDF) was released, and transfer of hemolymph
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from challenged mosquitoes induced hemocyte differentiation in naive recipient mosquitoes.
Furthermore, HDF transfer was sufficient to confer enhanced antiplasmodial immunity (205).
Understanding the molecular mechanism(s) that mediate hemocyte differentiation and trigger a
long-lasting state of enhanced immunity in insects will undoubtedly provide new insights into the
evolution of innate immune memory responses.
Epithelial Responses to Plasmodium and Complement Activation
To complete their development in the mosquito, Plasmodium ookinetes must traverse the midgut
epithelium and avoid being detected and lysed by themosquito complement-like system.Mosquito
midgut cells invaded by ookinetes are known to mount defense responses, such as expression of
high levels of NOS (206, 207). Investigators have proposed that these epithelial responses are
harmful to the parasite and that the rate of nitration is a major determinant of Plasmodium survival
(207–209). Biochemical studies in this system revealed that nitration in Plasmodium-invaded cells
is a two-step process in which the induction of NOS expression is followed by an increase in
peroxidase activity (209, 210), similar to what has been described for myeloperoxidase-mediated
nitration in vertebrate macrophages (211, 212).
As ookinetes complete their traversal of the mosquito midgut, they come in contact with
components of the mosquito complement-like system present in the mosquito hemolymph (the
serum-like fluid in the circulatory system of insects). The thioester-containing protein 1 (TEP1) is
similar to vertebrate complement factor C3 and circulates as a stable complex associated with two
proteins of the leucine-rich repeat family, LRIM1 and APL1 (213, 214). It is clear that TEP1 binds
to the surface of some parasites and is a critical component of a lytic complex (215). However,
because all ookinetes come in contact with TEP1 circulating in the hemolymph, it has been
difficult to understand why TEP1 binds to the surface of some ookinetes and triggers lysis, while
other parasites are spared.
An A. gambiae heme peroxidase (HPX2) and NADPH oxidase 5 (NOX5) were recently iden-
tified as key enzymes induced in ookinete-invaded midgut cells that, together with NOS, mediate
protein nitration (216). The HPX2/NOX5 system potentiates NO toxicity and is critical for
mosquitoes to mount an effective antiplasmodial response. Furthermore, these studies reveal that
epithelia nitration and TEP1-mediated lysis work sequentially and that epithelial nitration serves
as an opsonization-like system that promotes activation of the mosquito complement cascade.
Signaling Pathways Regulating Mosquito Antiplasmodial Immunity
Immune signaling pathways are among the most widely studied mechanisms of mosquito immune
activation. Comparative whole-genome sequencing analysis revealed that the genes mediating
intracellular signaling are highly conserved, particularly between mosquitoes and Drosophila, pro-
viding a useful starting point to identify genes composing individual pathways (217–221). Four sig-
naling cascades have been linked to immune activation and the killing of Plasmodium parasites: the
Toll, Imd, JNK, andSTATpathways (208, 222–226).Gene silencingby systemic injectionof dsRNA
into the mosquito circulatory system has been a powerful tool to disrupt or overactivate specific
signaling cascades. The effect of silencing positive regulators, such as transcription factors or genes
involved in signal transduction, or negative regulators that enhance signaling on Plasmodium infec-
tion, has been very informative. TheToll and Imd pathways target the ookinete stage of the parasite
and promote activation of the mosquito TEP1 complement-like system (222–224). Interestingly,
the Toll pathway is more effective against P. berghei (rodent malaria parasite), whereas the Imd
pathway limits infection with the humanmalaria parasite P. falciparum in several different anophe-
line mosquitoes (223). Recent experiments revealed that the transfer of hemocytes in which Toll
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signaling has been enhanced by silencing cactus (a suppressor gene) confers the antiplasmodial
activity against P. berghei parasites, indicating that hemocytes play an active role in regulating
complement activation through the Toll pathway (227). The JNK pathway also promotes
TEP1-mediated lysis by the complement-like system by regulating the expression of HPX2
and NOX5, the two enzymes that mediate midgut nitration, and by regulating the basal level of
TEP1 expression in hemocytes (228). It is noteworthy that these three signaling pathways, Toll,
Imd, and JNK, converge with TEP1 as a key effector of the complex that lyses the parasite. This
is reminiscent of the convergence of the classic, alternative, and lectin pathways of complement
activation in vertebrates. The STAT pathway targets Plasmodium parasites after they cross the
midgut and transform into the oocysts (226). This late-phase immune response limits oocyst
survival through the induction of NOS expression.
Undoubtedly, the different signaling pathways interact as a complex network that operates in
different compartments, and higher levels of organization and complexity are becoming apparent.
For example, a recent study revealed that activation of the Imd or Toll pathways induces expression
of different splicing factors that, in turn, generate specific isoforms of AgDscam, a hypervariable
PRR protein, through differential gene splicing (229). Furthermore, expression of these different
AgDscam isoforms results in species-specific antiplasmodial responses (229, 230).
Future challenges include identifying the effector genes that mediate the responses of different
signaling cascades and determining the tissues in which they are produced. In some cases, it is
possible to transfer cells (such as through the hemocyte transfer experiments described above) in
which different pathways have been activated and establish their effect on Plasmodium survival.
Broad expression analysis of specific tissues in which a given pathway is disrupted or overactive
can also be informative, and genetic systems to drive tissue-specific overexpression or silencing
are also being developed. This detailed analysis will also inform vector control strategies based on
manipulating immunological responses. For example, it would make it possible to overexpress or
silence certain pathway components using tissue-specific promoters that are transiently activated
at the precise time to maximize their effect on the parasite, while avoiding detrimental effects on
the mosquito.
Immune Evasion by Plasmodium Parasites
It is clear from animal model systems that mosquitoes have a complex immune system capable of
mounting robust and effective antiplasmodial responses. However, there are several reports that
disrupting the complement-like system has a modest effect (223, 231) or no effect (220, 221) when
A. gambiae is infected with some strains of the human parasite P. falciparum.
An A. gambiae strain selected to be refractory (R) to the simian malaria P. cynomolgi eliminates
most Plasmodium species, including P. falciparum strains from the New World, by forming a
melanotic capsule (deposition of melanin, a black insoluble pigment) around the dead parasites.
However, the A. gambiae R strain is highly susceptible to infection with some P. falciparum strains
of African origin where A. gambiae is the natural vector (222). Disruption of the complement-like
system prevents elimination of the P. falciparum 7G8 strain from Brazil but has no effect on the
intensity or prevalence of infection with NF54 parasites from Africa, indicating that the African
parasite lines are able to evade the A. gambiae immune system (221). Coinfection experiments
revealed that the immune response (or lack thereof ) to a parasite strain did not affect the fate
of other parasites present in the same mosquito midgut (221), suggesting that parasite survival is
determined by genetic differences between P. falciparum strains (221).
QTL mapping—using a genetic cross between the African GB4 strain that survives in
R mosquitoes and the Brazilian 7G8 strain that is eliminated—plus linkage group selection and
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functional genomics were recently combined to identify Pfs47 as the parasite gene that allows
P. falciparum parasites to evade the mosquito immune system (223). Disruption of Pfs47 (in a
NF54 genetic background that normally survives) resulted in parasite killing and melanization
that could be prevented by silencing TEP1, indicating that Pfs47 is necessary for NF54 parasites
to evade destruction by the mosquito complement system (223). Pfs47 is required for P. falciparum
to evade two well-defined antiplasmodial responses mediated by the complement-like system:
parasite killing/melanization and lysis without melanization. Genetic complementation of the
Pfs47 knockout line with theNF54 allele of Pfs47 completely reversed themelanization phenotype
in the R strain, confirming that this gene allele is sufficient for parasites to evade the mosquito
immune system (223).
Interestingly, Pfs47 is a highly polymorphic gene that exhibits strong population structure
and extreme fixation in non-African regions (224, 225). Our findings suggest that the population
structure of Pfs47 may be due to adaptation of P. falciparum to the different anopheles vector
species present in different geographical regions of the world. The evolution of Pfs47 apparently
promoted P. falciparum survival in A. gambiae mosquitoes and could be responsible for the very
high rates of malaria transmission in sub-Saharan Africa. Disruption of the immunomodulatory
activity of Pfs47 may be an effective target to reduce human malaria transmission.
There are 10 members of the 6-cystein protein family in P. falciparum (226). The function of
four of them that are expressed in the asexual erythrocytic stages of the parasite in the human host
is unknown (226, 229). It is well established that P. falciparum parasites can evade the vertebrate
immune system and elicit ineffective immune memory responses, resulting in persistent and re-
current infections (119, 230–231). This raises the intriguing possibility that other members of this
protein family may also have an immunomodulatory function in humans.
SUMMARY AND ROAD FORWARD
It is an exciting time in malaria immunity research. We now have the tools to make significant
progress in understanding the cellular andmolecularmechanismsunderlying several long-standing
phenomena in malaria immunity. In humans these include the paucity of sterilizing immunity
to the liver stage, the relatively rapid acquisition of immunity to severe disease, the acquired
control of inflammation, the slow acquisition of ultimately protective antibody immunity, and
the susceptibility to severe disease of only a small fraction of exposed children. In mosquitoes,
these include the genetic resistance to infection in mosquito populations and acquired innate
immune control of parasites in individual mosquitoes. The time is ripe for new investigators to
enter the field and contribute to the defeat of this devastating disease.
DISCLOSURE STATEMENT
The authors are not aware of any affiliations, memberships, funding, or financial holdings that
might be perceived as affecting the objectivity of this review.
ACKNOWLEDGMENTS
This work was supported by the Intramural Research Program of the National Institute of Allergy
and Infectious Diseases, National Institutes of Health.
LITERATURE CITED
1. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, et al. 2012. Global malaria mortality
between 1980 and 2010: a systematic analysis. Lancet 379:413–31



















































































IY32CH06-Pierce ARI 13 February 2014 11:33
2. Langhorne J, Ndungu FM, Sponaas AM, Marsh K. 2008. Immunity to malaria: more questions than
answers. Nat. Immunol. 9:725–32
3. Marsh K, Kinyanjui S. 2006. Immune effector mechanisms in malaria. Parasite Immunol. 28:51–60
4. Mueller I, GalinskiMR,TsuboiT, Arevalo-HerreraM,CollinsWE,KingCL. 2013.Natural acquisition
of immunity to Plasmodium vivax: epidemiological observations and potential targets. Adv. Parasitol.
81:77–131
5. Riley EM, Stewart VA. 2013. Immune mechanisms in malaria: new insights in vaccine development.
Nat. Med. 19:168–78
6. Miller LH,AckermanHC, SuXZ,WellemsTE. 2013.Malaria biology and disease pathogenesis: insights
for new treatments. Nat. Med. 19:156–67
7. MillerLH,Pierce SK. 2009.Perspective onmalaria eradication: Is eradicationpossiblewithoutmodifying
the mosquito? J. Infect. Dis. 200:1644–45
8. Roberts L, Enserink M. 2007. Malaria. Did they really say eradication? Science 318:1544–45
9. The RTS,S Clinical Trials Partnership. 2012. A phase 3 trial of RTS,S/AS01 malaria vaccine in African
infants. N. Engl. J. Med. 367:2284–95
10. Smith DL, Battle KE, Hay SI, Barker CM, Scott TW, McKenzie FE. 2012. Ross, Macdonald, and a
theory for the dynamics and control of mosquito-transmitted pathogens. PLoS Pathog. 8:e1002588
11. Molineaux L, Gramiccia G. 1980. The Garki Project: Research on the Epidemiology and Control of Malaria
in the Sudan Savanna of West Africa. Geneva: World Health Organization. 311 pp.
12. Sharma VP. 1996. Re-emergence of malaria in India. Indian J. Med. Res. 103:26–45
13. Macdonald G. 1957. The Epidemiology and Control of Malaria. Oxford, UK: Oxford Univ. Press
14. Mu J, Duan J, Makova KD, Joy DA, Huynh CQ, et al. 2002. Chromosome-wide SNPs reveal an ancient
origin for Plasmodium falciparum. Nature 418:323–26
15. Kwiatkowski DP. 2005. Howmalaria has affected the human genome and what human genetics can teach
us about malaria. Am. J. Hum. Genet. 77:171–92
16. Molineaux L. 1985. The impact of parasitic diseases and their control on mortality, with emphasis on
malaria and Africa. In Health Policy, Social Policy, and Mortality Prospects, ed. J Vallin, A Lopez, pp. 13–44.
Liege: Ordina Ed.
17. Gardner MJ, Hall N, Fung E, White O, Berriman M, et al. 2002. Genome sequence of the human
malaria parasite Plasmodium falciparum. Nature 419:498–511
18. Gueirard P, Tavares J, Thiberge S, Bernex F, Ishino T, et al. 2010. Development of the malaria parasite
in the skin of the mammalian host. Proc. Natl. Acad. Sci. USA 107:18640–45
19. Mota MM, Pradel G, Vanderberg JP, Hafalla JC, Frevert U, et al. 2001. Migration of Plasmodium
sporozoites through cells before infection. Science 291:141–44
20. Sturm A, Amino R, van de Sand C, Regen T, Retzlaff S, et al. 2006. Manipulation of host hepatocytes
by the malaria parasite for delivery into liver sinusoids. Science 313:1287–90
21. Miller LH, Baruch DI, Marsh K, Doumbo OK. 2002. The pathogenic basis of malaria.Nature 415:673–
79
22. Wykes MN, Good MF. 2009. What have we learnt from mouse models for the study of malaria? Eur. J.
Immunol. 39:2004–7
23. Sauerwein RW, Roestenberg M, Moorthy VS. 2011. Experimental human challenge infections can
accelerate clinical malaria vaccine development. Nat. Rev. Immunol. 11:57–64
24. Engwerda CR, Minigo G, Amante FH,McCarthy JS. 2012. Experimentally induced blood stage malaria
infection as a tool for clinical research. Trends Parasitol. 28:515–21
25. Tran TM, Samal B, Kirkness E, Crompton PD. 2012. Systems immunology of human malaria. Trends
Parasitol. 28:248–57
26. Offeddu V, Thathy V, Marsh K, Matuschewski K. 2012. Naturally acquired immune responses against
Plasmodium falciparum sporozoites and liver infection. Int. J. Parasitol. 42:535–48
27. Tran TM, Li S, Doumbo S, Doumtabe D, Huang CY, et al. 2013. An intensive longitudinal cohort
study of Malian children and adults reveals no evidence of acquired immunity to Plasmodium falciparum
infection. Clin. Infect. Dis. 57:40–47
28. Honda T, Miyachi Y, Kabashima K. 2011. Regulatory T cells in cutaneous immune responses. J. Der-
matol. Sci. 63:75–82



















































































IY32CH06-Pierce ARI 13 February 2014 11:33
29. Crispe IN. 2009. The liver as a lymphoid organ. Annu. Rev. Immunol. 27:147–63
30. Guilbride DL, Gawlinski P, Guilbride PD. 2010. Why functional pre-erythrocytic and bloodstage
malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model.
PLoS ONE 5:e10685
31. da Silva HB, Caetano SS, Monteiro I, Gomez-Conde I, Hanson K, et al. 2012. Early skin immunological
disturbance after Plasmodium-infected mosquito bites. Cell. Immunol. 277:22–32
32. Good MF, Doolan DL. 2010. Malaria vaccine design: immunological considerations. Immunity 33:555–
66
33. Usynin I, Klotz C, Frevert U. 2007. Malaria circumsporozoite protein inhibits the respiratory burst in
Kupffer cells. Cell. Microbiol. 9:2610–28
34. Nussenzweig RS, Vanderberg J,MostH,OrtonC. 1967. Protective immunity produced by the injection
of X-irradiated sporozoites of Plasmodium berghei. Nature 216:160–62
35. Gwadz RW, Cochrane AH, Nussenzweig V, Nussenzweig RS. 1979. Preliminary studies on vaccination
of rhesus monkeys with irradiated sporozoites of Plasmodium knowlesi and characterization of surface
antigens of these parasites. Bull. World Health Organ. 57(Suppl. 1):165–73
36. Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, et al. 2002. Protection of humans against malaria
by immunizationwith radiation-attenuatedPlasmodium falciparum sporozoites. J. Infect. Dis. 185:1155–64
37. Vaughan AM, Wang R, Kappe SH. 2010. Genetically engineered, attenuated whole-cell vaccine ap-
proaches for malaria. Hum. Vaccine 6:107–13
38. Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, et al. 2009. Protection against a malaria
challenge by sporozoite inoculation. N. Engl. J. Med. 361:468–77
39. Epstein JE, Tewari K, Lyke KE, Sim BK, Billingsley PF, et al. 2011. Live attenuated malaria vaccine
designed to protect through hepatic CD8+ T cell immunity. Science 334:475–80
40. Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, et al. 2013. Protection against malaria by
intravenous immunization with a nonreplicating sporozoite vaccine. Science 341:1359–65
41. Barry AE, Schultz L, Buckee CO, Reeder JC. 2009. Contrasting population structures of the genes
encoding ten leading vaccine-candidate antigens of the human malaria parasite, Plasmodium falciparum.
PLoS ONE 4:e8497
42. Trieu A, Kayala MA, Burk C, Molina DM, Freilich DA, et al. 2011. Sterile protective immunity to
malaria is associated with a panel of novel P. falciparum antigens. Mol. Cell. Proteomics 10:M111.007948
43. Krzych U, Lyon JA, Jareed T, Schneider I, Hollingdale MR, et al. 1995. T lymphocytes from volunteers
immunized with irradiated Plasmodium falciparum sporozoites recognize liver and blood stage malaria
antigens. J. Immunol. 155:4072–77
44. Doolan DL, Southwood S, Freilich DA, Sidney J, Graber NL, et al. 2003. Identification of Plasmodium
falciparum antigens by antigenic analysis of genomic and proteomic data. Proc. Natl. Acad. Sci. USA
100:9952–57
45. Roestenberg M, Teirlinck AC, McCall MB, Teelen K, Makamdop KN, et al. 2011. Long-term pro-
tection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet
377:1770–76
46. Bijker EM, Bastiaens GJ, Teirlinck AC, van Gemert GJ, Graumans W, et al. 2013. Protection against
malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic
immunity. Proc. Natl. Acad. Sci. USA 110:7862–67
47. Sinnis P, Zavala F. 2012. The skin: where malaria infection and the host immune response begin. Semin.
Immunopathol. 34:787–92
48. Lindner SE, Miller JL, Kappe SH. 2012. Malaria parasite pre-erythrocytic infection: preparation meets
opportunity. Cell. Microbiol. 14:316–24
49. Chakravarty S, Cockburn IA, Kuk S, Overstreet MG, Sacci JB, Zavala F. 2007. CD8+ T lymphocytes
protective against malaria liver stages are primed in skin-draining lymph nodes. Nat. Med. 13:1035–41
50. Hafalla JC, Silvie O, Matuschewski K. 2011. Cell biology and immunology of malaria. Immunol. Rev.
240:297–316
51. Overstreet MG, Cockburn IA, Chen YC, Zavala F. 2008. Protective CD8+ T cells against Plasmodium
liver stages: immunobiology of an “unnatural” immune response. Immunol. Rev. 225:272–83



















































































IY32CH06-Pierce ARI 13 February 2014 11:33
52. Cockburn IA, Tse SW, Radtke AJ, Srinivasan P, Chen YC, et al. 2011. Dendritic cells and hepatocytes
use distinct pathways to process protective antigen from Plasmodium in vivo. PLoS Pathog. 7:e1001318
53. Jung S,UnutmazD,WongP, SanoG,De los SantosK, et al. 2002. In vivo depletion ofCD11c+ dendritic
cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity 17:211–20
54. Hafalla JC, BauzaK, Friesen J,Gonzalez-AseguinolazaG,Hill AV,Matuschewski K. 2013. Identification
of targets ofCD8+ Tcell responses tomalaria liver stages by genome-wide epitope profiling.PLoSPathog.
9:e1003303
55. Murphy SC, Kas A, Stone BC, Bevan MJ. 2013. A T-cell response to a liver-stage Plasmodium antigen is
not boosted by repeated sporozoite immunizations. Proc. Natl. Acad. Sci. USA 110:6055–60
56. Cockburn IA, Chen YC, Overstreet MG, Lees JR, van Rooijen N, et al. 2010. Prolonged antigen
presentation is required for optimal CD8+ T cell responses against malaria liver stage parasites. PLoS
Pathog. 6:e1000877
57. Kaech SM, Ahmed R. 2001. Memory CD8+ T cell differentiation: initial antigen encounter triggers a
developmental program in naive cells. Nat. Immunol. 2:415–22
58. Schmidt NW, Butler NS, Badovinac VP, Harty JT. 2010. Extreme CD8 T cell requirements for
anti-malarial liver-stage immunity following immunization with radiation attenuated sporozoites. PLoS
Pathog. 6:e1000998
59. Webster DP, Dunachie S, Vuola JM, Berthoud T, Keating S, et al. 2005. Enhanced T cell-mediated
protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified
vaccinia virus Ankara. Proc. Natl. Acad. Sci. USA 102:4836–41
60. Duffy PE, Sahu T, Akue A,MilmanN, Anderson C. 2012. Pre-erythrocytic malaria vaccines: identifying
the targets. Expert Rev. Vaccines 11:1261–80
61. Vanderberg JP, Frevert U. 2004. Intravital microscopy demonstrating antibody-mediated immobilisa-
tion of Plasmodium berghei sporozoites injected into skin by mosquitoes. Int. J. Parasitol. 34:991–96
62. Sinnis P, Coppi A. 2007. A long andwinding road: thePlasmodium sporozoite’s journey in themammalian
host. Parasitol. Int. 56:171–78
63. Di Meglio P, Perera GK, Nestle FO. 2011. The multitasking organ: recent insights into skin immune
function. Immunity 35:857–69
64. Takebe T, Sekine K, Enomura M, Koike H, Kimura M, et al. 2013. Vascularized and functional human
liver from an iPSC-derived organ bud transplant. Nature 499:481–84
65. Nussenzweig RS, Vanderberg J, Most H, Orton C. 1967. Protective immunity produced by the injection
of X-irradiated sporozoites of Plasmodium berghei. Nature 216:160–62
66. Casares S, Brumeanu TD, Richie TL. 2010. The RTS,S malaria vaccine. Vaccine 28:4880–94
67. Moorthy VS, BallouWR. 2009. Immunological mechanisms underlying protection mediated by RTS,S:
a review of the available data. Malar. J. 8:312
68. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, et al. 2011. First results of phase
3 trial of RTS,S/AS01 malaria vaccine in African children. N. Engl. J. Med. 365:1863–75
69. Bejon P, Mwacharo J, Kai O, Mwangi T, Milligan P, et al. 2006. A phase 2b randomised trial of the
candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin.
Trials 1:e29
70. Moorthy VS, Imoukhuede EB,Milligan P, BojangK, Keating S, et al. 2004. A randomised, double-blind,
controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults.
PLoS Med. 1:e33
71. Zevering Y, Houghten RA, Frazer IH, GoodMF. 1990. Major population differences in T cell response
to a malaria sporozoite vaccine candidate. Int. Immunol. 2:945–55
72. Hartgers FC, YazdanbakhshM. 2006. Co-infection of helminths andmalaria: modulation of the immune
responses to malaria. Parasite Immunol. 28:497–506
73. Schaible UE, Kaufmann SH. 2007.Malnutrition and infection: complexmechanisms and global impacts.
PLoS Med. 4:e115
74. Molloy MJ, Bouladoux N, Belkaid Y. 2012. Intestinal microbiota: shaping local and systemic immune
responses. Semin. Immunol. 24:58–66
75. Yoshimoto S, LooTM, Atarashi K, KandaH, Sato S, et al. 2013. Obesity-induced gut microbial metabo-
lite promotes liver cancer through senescence secretome. Nature 499:97–101



















































































IY32CH06-Pierce ARI 13 February 2014 11:33
76. Kraemer SM, Smith JD. 2006. A family affair: var genes, PfEMP1 binding, and malaria disease. Curr.
Opin. Microbiol. 9:374–80
77. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, et al. 2013. Severe malaria is associated with
parasite binding to endothelial protein C receptor. Nature 498:502–5
78. Clark IA, Alleva LM, Mills AC, Cowden WB. 2004. Pathogenesis of malaria and clinically similar
conditions. Clin. Microbiol. Rev. 17:509–39
79. Hunt NH, Grau GE. 2003. Cytokines: accelerators and brakes in the pathogenesis of cerebral malaria.
Trends Immunol. 24:491–99
80. White NJ, Turner GD, Day NP, Dondorp AM. 2013. Lethal malaria: Marchiafava and Bignami were
right. J. Infect. Dis. 208:192–98
81. Clark IA, Alleva LM. 2009. Is humanmalarial coma caused, ormerely deepened, by sequestration?Trends
Parasitol. 25:314–18
82. Collins WE, Jeffery GM. 1999. A retrospective examination of secondary sporozoite- and trophozoite-
induced infections with Plasmodium falciparum: development of parasitologic and clinical immunity fol-
lowing secondary infection. Am. J. Trop. Med. Hyg. 61:20–35
83. DayNP,HienTT, SchollaardtT,LocPP,ChuongLV, et al. 1999.The prognostic and pathophysiologic
role of pro- and antiinflammatory cytokines in severe malaria. J. Infect. Dis. 180:1288–97
84. Lyke KE, Burges R, Cissoko Y, Sangare L, Dao M, et al. 2004. Serum levels of the proinflammatory
cytokines interleukin-1 beta (IL-1β), IL-6, IL-8, IL-10, tumor necrosis factor alpha, and IL-12(p70)
in Malian children with severe Plasmodium falciparum malaria and matched uncomplicated malaria or
healthy controls. Infect. Immun. 72:5630–37
85. Walther M, Woodruff J, Edele F, Jeffries D, Tongren JE, et al. 2006. Innate immune responses to
human malaria: heterogeneous cytokine responses to blood-stage Plasmodium falciparum correlate with
parasitological and clinical outcomes. J. Immunol. 177:5736–45
86. Krishnegowda G, Hajjar AM, Zhu J, Douglass EJ, Uematsu S, et al. 2005. Induction of proinflammatory
responses in macrophages by the glycosylphosphatidylinositols of Plasmodium falciparum: cell signaling
receptors, glycosylphosphatidylinositol (GPI) structural requirement, and regulation of GPI activity.
J. Biol. Chem. 280:8606–16
87. Shio MT, Eisenbarth SC, Savaria M, Vinet AF, Bellemare MJ, et al. 2009. Malarial hemozoin activates
the NLRP3 inflammasome through Lyn and Syk kinases. PLoS Pathog. 5:e1000559
88. ParrocheP,LauwFN,GoutagnyN,LatzE,MonksBG, et al. 2007.Malaria hemozoin is immunologically
inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. Proc.
Natl. Acad. Sci. USA 104:1919–24
89. Sharma S, DeOliveira RB, Kalantari P, Parroche P, GoutagnyN, et al. 2011. Innate immune recognition
of an AT-rich stem-loop DNA motif in the Plasmodium falciparum genome. Immunity 35:194–207
90. Claessens A, Adams Y, Ghumra A, Lindergard G, Buchan CC, et al. 2012. A subset of group A-like var
genes encodes the malaria parasite ligands for binding to human brain endothelial cells. Proc. Natl. Acad.
Sci. USA 109:E1772–81
91. AvrilM,Tripathi AK, Brazier AJ, Andisi C, Janes JH, et al. 2012. A restricted subset of var genesmediates
adherence of Plasmodium falciparum-infected erythrocytes to brain endothelial cells. Proc. Natl. Acad. Sci.
USA 109:10158–59
92. Lavstsen T, Turner L, Saguti F, Magistrado P, Rask TS, et al. 2012. Plasmodium falciparum erythrocyte
membrane protein 1 domain cassettes 8 and 13 are associated with severe malaria in children. Proc. Natl.
Acad. Sci. USA 109:E1791–800
93. Waisberg M, Cerqueira GC, Yager SB, Francischetti IM, Lu J, et al. 2012. Plasmodium falciparum
merozoite surface protein 1 blocks the proinflammatory protein S100P. Proc. Natl. Acad. Sci. USA
109:5429–34
94. Stevenson MM, Riley EM. 2004. Innate immunity to malaria. Nat. Rev. Immunol. 4:169–80
95. Urban BC, Ing R, Stevenson MM. 2005. Early interactions between blood-stage Plasmodium parasites
and the immune system. Curr. Top. Microbiol. Immunol. 297:25–70
96. Guermonprez P, Helft J, Claser C, Deroubaix S, Karanje H, et al. 2013. Inflammatory Flt3l is essential
to mobilize dendritic cells and for T cell responses during Plasmodium infection. Nat. Med. 19:730–38



















































































IY32CH06-Pierce ARI 13 February 2014 11:33
97. Porcherie A, Mathieu C, Peronet R, Schneider E, Claver J, et al. 2011. Critical role of the neutrophil-
associated high-affinity receptor for IgE in the pathogenesis of experimental cerebral malaria. J. Exp.
Med. 208:2225–36
98. Hansen DS, D’Ombrain MC, Schofield L. 2007. The role of leukocytes bearing natural killer complex
receptors and killer immunoglobulin-like receptors in the immunology of malaria. Curr. Opin. Immunol.
19:416–23
99. Horowitz A, Newman KC, Evans JH, Korbel DS, Davis DM, Riley EM. 2010. Cross-talk between
T cells and NK cells generates rapid effector responses to Plasmodium falciparum-infected erythrocytes.
J. Immunol. 184:6043–52
100. Schofield L, Mueller I. 2006. Clinical immunity to malaria. Curr. Mol. Med. 6:205–21
101. Grau GE, Taylor TE, Molyneux ME, Wirima JJ, Vassalli P, et al. 1989. Tumor necrosis factor and
disease severity in children with falciparum malaria. N. Engl. J. Med. 320:1586–91
102. Sinton JA. 1938. Immunity or tolerance in malarial infections. Proc. R. Soc. Med. 31:1298–302
103. RubensteinM,Mulholland JH, Jeffery GM,Wolff SM. 1965.Malaria induced endotoxin tolerance. Proc.
Soc. Exp. Biol. Med. 118:283–87
104. Omer FM, Riley EM. 1998. Transforming growth factor β production is inversely correlated with
severity of murine malaria infection. J. Exp. Med. 188:39–48
105. Li C, Corraliza I, Langhorne J. 1999. A defect in interleukin-10 leads to enhanced malarial disease in
Plasmodium chabaudi chabaudi infection in mice. Infect. Immun. 67:4435–42
106. Dodoo D, Omer FM, Todd J, Akanmori BD, Koram KA, Riley EM. 2002. Absolute levels and ratios
of proinflammatory and anti-inflammatory cytokine production in vitro predict clinical immunity to
Plasmodium falciparum malaria. J. Infect. Dis. 185:971–79
107. Walther M, Jeffries D, Finney OC, Njie M, Ebonyi A, et al. 2009. Distinct roles for FOXP3 and FOXP3
CD4T cells in regulating cellular immunity to uncomplicated and severe Plasmodium falciparummalaria.
PLoS Pathog. 5:e1000364
108. Riley EM, Wahl S, Perkins DJ, Schofield L. 2006. Regulating immunity to malaria. Parasite Immunol.
28:35–49
109. Finney OC, Riley EM,Walther M. 2010. Regulatory T cells in malaria—friend or foe? Trends Immunol.
31:63–70
110. Spence PJ, Langhorne J. 2012. T cell control of malaria pathogenesis. Curr. Opin. Immunol. 24:444–48
111. Deleted in proof
112. Baliraine FN, Afrane YA, Amenya DA, Bonizzoni M, Menge DM, et al. 2009. High prevalence of
asymptomatic Plasmodium falciparum infections in a highland area of western Kenya: a cohort study.
J. Infect. Dis. 200:66–74
113. Bottius E, Guanzirolli A, Trape JF, Rogier C, Konate L, Druilhe P. 1996. Malaria: even more chronic in
nature than previously thought; evidence for subpatent parasitaemia detectable by the polymerase chain
reaction. Trans. R. Soc. Trop. Med. Hyg. 90:15–19
114. O’Garra A, Vieira P. 2007. TH1 cells control themselves by producing interleukin-10.Nat. Rev. Immunol.
7:425–28
115. Gerosa F, Nisii C, Righetti S, Micciolo R, Marchesini M, et al. 1999. CD4+ T cell clones produc-
ing both interferon-γ and interleukin-10 predominate in bronchoalveolar lavages of active pulmonary
tuberculosis patients. Clin. Immunol. 92:224–34
116. Nylen S, Maurya R, Eidsmo L, Manandhar KD, Sundar S, Sacks D. 2007. Splenic accumulation of
IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leish-
maniasis. J. Exp. Med. 204:805–17
117. Anderson CF, Oukka M, Kuchroo VJ, Sacks D. 2007. CD4+CD25−Foxp3− Th1 cells are the source of
IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J. Exp. Med. 204:285–97
118. Jankovic D, Kullberg MC, Feng CG, Goldszmid RS, Collazo CM, et al. 2007. Conventional T-
bet+Foxp3− Th1 cells are the major source of host-protective regulatory IL-10 during intracellular
protozoan infection. J. Exp. Med. 204:273–83
119. Portugal S, Pierce SK, Crompton PD. 2013. Young lives lost as B cells falter: what we are learning about
antibody responses in malaria. J. Immunol. 190:3039–46



















































































IY32CH06-Pierce ARI 13 February 2014 11:33
120. Cohen S,McGregor IA,Carrington S. 1961.Gamma-globulin and acquired immunity to humanmalaria.
Nature 192:733–37
121. Crompton PD, Pierce SK, Miller LH. 2010. Advances and challenges in malaria vaccine development.
J. Clin. Investig. 120:4168–78
122. Takala SL, PloweCV. 2009.Genetic diversity andmalaria vaccine design, testing and efficacy: preventing
and overcoming “vaccine resistant malaria.” Parasite Immunol. 31:560–73
123. Scherf A, Lopez-Rubio JJ, Riviere L. 2008. Antigenic variation in Plasmodium falciparum. Annu. Rev.
Microbiol. 62:445–70
124. Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Ouattara A, et al. 2011. A field trial to assess a
blood-stage malaria vaccine. N. Engl. J. Med. 365:1004–13
125. Hayton K, Gaur D, Liu A, Takahashi J, Henschen B, et al. 2008. Erythrocyte binding protein PfRH5
polymorphisms determine species-specific pathways of Plasmodium falciparum invasion. Cell Host Microbe
4:40–51
126. Baum J, Chen L, Healer J, Lopaticki S, Boyle M, et al. 2009. Reticulocyte-binding protein homologue
5—an essential adhesin involved in invasion of human erythrocytes by Plasmodium falciparum. Int. J.
Parasitol. 39:371–80
127. Crosnier C, Bustamante LY, Bartholdson SJ, Bei AK, Theron M, et al. 2011. Basigin is a receptor
essential for erythrocyte invasion by Plasmodium falciparum. Nature 480:534–37
128. Douglas AD, Williams AR, Illingworth JJ, Kamuyu G, Biswas S, et al. 2011. The blood-stage malaria
antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat. Commun.
2:601
129. TranTM,Ongoiba A, Coursen J, Crosnier C,Diouf A, et al. 2013.Naturally acquired antibodies specific
for Plasmodium falciparum RH5 inhibit parasite growth and predict protection from malaria. J. Infect.
Dis. In press. doi: 10.1093/infdis/jit553
130. Williams AR, Douglas AD, Miura K, Illingworth JJ, Choudhary P, et al. 2012. Enhancing blockade of
Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and
other merozoite antigens. PLoS Pathog. 8:e1002991
131. Richards JS, Arumugam TU, Reiling L, Healer J, Hodder AN, et al. 2013. Identification and prioriti-
zation of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria
for vaccine and biomarker development. J. Immunol. 191:795–809
132. Patel SD, Ahouidi AD, Bei AK, Dieye TN, Mboup S, et al. 2013. Plasmodium falciparum merozoite
surface antigen, PfRH5, elicits detectable levels of invasion-inhibiting antibodies in humans. J. Infect.
Dis. 208:1679–87
133. Chan JA, Howell KB, Reiling L, Ataide R, Mackintosh CL, et al. 2012. Targets of antibodies against
Plasmodium falciparum-infected erythrocytes in malaria immunity. J. Clin. Investig. 122:3227–38
134. Bull PC, Lowe BS, Kortok M, Molyneux CS, Newbold CI, Marsh K. 1998. Parasite antigens on the
infected red cell surface are targets for naturally acquired immunity to malaria. Nat. Med. 4:358–60
135. JiangL,Mu J, ZhangQ,NiT, SrinivasanP, et al. 2013. PfSETvsmethylation of histoneH3K36 represses
virulence genes in Plasmodium falciparum. Nature 499:223–27
136. McCarthy JS, GoodMF. 2010. Whole parasite blood stage malaria vaccines: a convergence of evidence.
Hum. Vaccine 6:114–23
137. Pinzon-Charry A, McPhun V, Kienzle V, Hirunpetcharat C, Engwerda C, et al. 2010. Low doses of
killed parasite in CpG elicit vigorous CD4+ T cell responses against blood-stage malaria in mice. J. Clin.
Investig. 120:2967–78
138. Tarlinton D, Good-Jacobson K. 2013. Diversity among memory B cells: origin, consequences, and
utility. Science 341:1205–11
139. Amanna IJ, Carlson NE, Slifka MK. 2007. Duration of humoral immunity to common viral and vaccine
antigens. N. Engl. J. Med. 357:1903–15
140. Crompton PD, Kayala MA, Traore B, Kayentao K, Ongoiba A, et al. 2010. A prospective analysis of
the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc.
Natl. Acad. Sci. USA 107:6958–63
141. Kinyanjui SM, ConwayDJ, Lanar DE,Marsh K. 2007. IgG antibody responses to Plasmodium falciparum
merozoite antigens in Kenyan children have a short half-life. Malar. J. 6:82



















































































IY32CH06-Pierce ARI 13 February 2014 11:33
142. Fonjungo PN, Elhassan IM, Cavanagh DR, Theander TG, Hviid L, et al. 1999. A longitudinal study of
human antibody responses to Plasmodium falciparum rhoptry-associated protein 1 in a region of seasonal
and unstable malaria transmission. Infect. Immun. 67:2975–85
143. Dorfman JR, BejonP,NdunguFM,Langhorne J,KortokMM, et al. 2005. B cellmemory to 3Plasmodium
falciparum blood-stage antigens in a malaria-endemic area. J. Infect. Dis. 191:1623–30
144. Nogaro SI, Hafalla JC, Walther B, Remarque EJ, Tetteh KK, et al. 2011. The breadth, but not the
magnitude, of circulating memory B cell responses to P. falciparum increases with age/exposure in an
area of low transmission. PLoS ONE 6:e25582
145. Wipasa J, Suphavilai C, Okell LC, Cook J, Corran PH, et al. 2010. Long-lived antibody and B cell
memory responses to the human malaria parasites, Plasmodium falciparum and Plasmodium vivax. PLoS
Pathog. 6:e1000770
146. Ndungu FM, Lundblom K, Rono J, Illingworth J, Eriksson S, Farnert A. 2013. Long-lived Plasmodium
falciparum specific memory B cells in naturally exposed Swedish travelers. Eur. J. Immunol. 43:2919–29
147. Weiss GE, Traore B, Kayentao K, Ongoiba A, Doumbo S, et al. 2010. The Plasmodium falciparum-
specific human memory B cell compartment expands gradually with repeated malaria infections. PLoS
Pathog. 6:e1000912
148. Ndungu FM, Olotu A, Mwacharo J, NyondaM, Apfeld J, et al. 2012. Memory B cells are a more reliable
archive for historical antimalarial responses than plasma antibodies in no-longer exposed children. Proc.
Natl. Acad. Sci. USA 109:8247–52
149. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R. 2003. Cutting edge: long-term
B cell memory in humans after smallpox vaccination. J. Immunol. 171:4969–73
150. Moir S, Ho J, Malaspina A, Wang W, DiPoto AC, et al. 2008. Evidence for HIV-associated B cell
exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J. Exp.
Med. 205:1797–805
151. Charles ED, Green RM, Marukian S, Talal AH, Lake-Bakaar GV, et al. 2008. Clonal expansion of
immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Blood 111:1344–56
152. Weiss GE, Crompton PD, Li S, Walsh LA, Moir S, et al. 2009. Atypical memory B cells are greatly
expanded in individuals living in a malaria-endemic area. J. Immunol. 183:2176–82
153. Illingworth J, ButlerNS,RoetynckS,Mwacharo J, Pierce SK, et al. 2013.Chronic exposure toPlasmodium
falciparum is associated with phenotypic evidence of B and T cell exhaustion. J. Immunol. 190:1038–47
154. Muellenbeck MF, Ueberheide B, Amulic B, Epp A, Fenyo D, et al. 2013. Atypical and classical memory
B cells produce Plasmodium falciparum neutralizing antibodies. J. Exp. Med. 210:389–99
155. Butler NS, Moebius J, Pewe LL, Traore B, Doumbo OK, et al. 2012. Therapeutic blockade of PD-L1
and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nat. Immunol. 13:188–95
156. Donati D, Mok B, Chene A, Xu H, Thangarajh M, et al. 2006. Increased B cell survival and preferential
activation of the memory compartment by a malaria polyclonal B cell activator. J. Immunol. 177:3035–44
157. Nduati E, Gwela A, Karanja H, Mugyenyi C, Langhorne J, et al. 2011. The plasma concentration of the
B cell activating factor is increased in children with acute malaria. J. Infect. Dis. 204:962–70
158. Scholzen A, Sauerwein RW. 2013. How malaria modulates memory: activation and dysregulation of B
cells in Plasmodium infection. Trends Parasitol. 29:252–62
159. Crompton PD, Mircetic M, Weiss G, Baughman A, Huang CY, et al. 2009. The TLR9 ligand CpG
promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals.
J. Immunol. 182:3318–26
160. Traore B, Kone Y, Doumbo S, Doumtabe D, Traore A, et al. 2009. The TLR9 agonist CpG fails to
enhance the acquisition of Plasmodium falciparum-specificmemory B cells in semi-immune adults inMali.
Vaccine 27:7299–303
161. Rogerson SJ, Hviid L, Duffy PE, Leke RF, Taylor DW. 2007. Malaria in pregnancy: pathogenesis and
immunity. Lancet Infect. Dis. 7:105–17
162. Marsh K, Forster D, Waruiru C, Mwangi I, Winstanley M, et al. 1995. Indicators of life-threatening
malaria in African children. N. Engl. J. Med. 332:1399–404
163. Grau GE, Craig AG. 2012. Cerebral malaria pathogenesis: revisiting parasite and host contributions.
Future Microbiol. 7:291–302



















































































IY32CH06-Pierce ARI 13 February 2014 11:33
164. Shikani HJ, Freeman BD, Lisanti MP, Weiss LM, Tanowitz HB, Desruisseaux MS. 2012. Cerebral
malaria: We have come a long way. Am. J. Pathol. 181:1484–92
165. Lundblom K, Murungi L, Nyaga V, Olsson D, Rono J, et al. 2013. Plasmodium falciparum infection
patterns since birth and risk of severe malaria: a nested case-control study in children on the coast of
Kenya. PLoS ONE 8:e56032
166. Lackritz EM, Campbell CC, Ruebush TK 2nd, Hightower AW,WakubeW, et al. 1992. Effect of blood
transfusion on survival among children in a Kenyan hospital. Lancet 340:524–28
167. Gupta S, SnowRW,DonnellyCA,MarshK,NewboldC. 1999. Immunity to non-cerebral severemalaria
is acquired after one or two infections. Nat. Med. 5:340–43
168. Alcais A, Quintana-Murci L, Thaler DS, Schurr E, Abel L, Casanova JL. 2010. Life-threatening infec-
tious diseases of childhood: single-gene inborn errors of immunity? Ann. N.Y. Acad. Sci. 1214:18–33
169. Jallow M, Teo YY, Small KS, Rockett KA, Deloukas P, et al. 2009. Genome-wide and fine-resolution
association analysis of malaria in West Africa. Nat. Genet. 41:657–65
170. Timmann C, Thye T, Vens M, Evans J, May J, et al. 2012. Genome-wide association study indicates
two novel resistance loci for severe malaria. Nature 489:443–46
171. Fox LL, Taylor TE, Pensulo P, Liomba A, Mpakiza A, et al. 2013. Histidine-rich protein 2 plasma
levels predict progression to cerebral malaria inMalawian children with Plasmodium falciparum infection.
J. Infect. Dis. 208:500–503
172. Fried M, Duffy PE. 1996. Adherence of Plasmodium falciparum to chondroitin sulfate A in the human
placenta. Science 272:1502–4
173. AvrilM,Tripathi AK, Brazier AJ, Andisi C, Janes JH, et al. 2012. A restricted subset of var genesmediates
adherence of Plasmodium falciparum-infected erythrocytes to brain endothelial cells. Proc. Natl. Acad. Sci.
USA 109:E1782–90
174. Lavstsen T, Turner L, Saguti F, Magistrado P, Rask TS, et al. 2012. Plasmodium falciparum erythrocyte
membrane protein 1 domain cassettes 8 and 13 are associated with severe malaria in children. Proc. Natl.
Acad. Sci. USA 109:E1791–800
175. Craig AG, Grau GE, Janse C, Kazura JW, Milner D, et al. 2012. The role of animal models for research
on severe malaria. PLoS Pathog. 8:e1002401
176. Milner DA Jr. 2010. Rethinking cerebral malaria pathology. Curr. Opin. Infect. Dis. 23:456–63
177. Belnoue E, Kayibanda M, Vigario AM, Deschemin JC, van Rooijen N, et al. 2002. On the pathogenic
role of brain-sequestered αβCD8+ T cells in experimental cerebral malaria. J. Immunol. 169:6369–75
178. Chen L, Zhang Z, Sendo F. 2000. Neutrophils play a critical role in the pathogenesis of experimental
cerebral malaria. Clin. Exp. Immunol. 120:125–33
179. Howland SW, Poh CM, Gun SY, Claser C, Malleret B, et al. 2013. Brain microvessel cross-presentation
is a hallmark of experimental cerebral malaria. EMBO Mol. Med. 5:984–99
180. Pais TF, Chatterjee S. 2005. Brain macrophage activation in murine cerebral malaria precedes accumu-
lation of leukocytes and CD8+ T cell proliferation. J. Neuroimmunol. 163:73–83
181. Waisberg M, Tarasenko T, Vickers BK, Scott BL, Willcocks LC, et al. 2011. Genetic susceptibility
to systemic lupus erythematosus protects against cerebral malaria in mice. Proc. Natl. Acad. Sci. USA
108:1122–27
182. Togbe D, Schofield L, Grau GE, Schnyder B, Boissay V, et al. 2007. Murine cerebral malaria develop-
ment is independent of Toll-like receptor signaling. Am. J. Pathol. 170:1640–48
183. Coban C, Ishii KJ, Uematsu S, Arisue N, Sato S, et al. 2007. Pathological role of Toll-like receptor
signaling in cerebral malaria. Int. Immunol. 19:67–79
184. RudinW,FavreN, BordmannG,Ryffel B. 1997. Interferon-γis essential for the development of cerebral
malaria. Eur. J. Immunol. 27:810–15
185. Engwerda CR, Mynott TL, Sawhney S, DeSouza JB, Bickle QD, Kaye PM. 2002. Locally up-regulated
lymphotoxin α, not systemic tumor necrosis factor α, is the principle mediator of murine cerebral
malaria. J. Exp. Med. 195:1371–77
186. Favre N, Da Laperousaz C, Ryffel B, Weiss NA, Imhof BA, et al. 1999. Role of ICAM-1 (CD54) in the
development of murine cerebral malaria. Microbes Infect. 1:961–68
187. Molokhia M, McKeigue P. 2006. Systemic lupus erythematosus: genes versus environment in high risk
populations. Lupus 15:827–32



















































































IY32CH06-Pierce ARI 13 February 2014 11:33
188. Bolland S, Ravetch JV. 2000. Spontaneous autoimmune disease in FcγRIIB-deficient mice results from
strain-specific epistasis. Immunity 13:277–85
189. Deane JA, Pisitkun P, Barrett RS, Feigenbaum L, Town T, et al. 2007. Control of Toll-like receptor 7
expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity 27:801–10
190. Clatworthy MR, Willcocks L, Urban B, Langhorne J, Williams TN, et al. 2007. Systemic lupus
erythematosus-associated defects in the inhibitory receptor FcγRIIb reduce susceptibility to malaria.
Proc. Natl. Acad. Sci. USA 104:7169–74
191. Willcocks LC, Carr EJ, Niederer HA, Rayner TF, Williams TN, et al. 2010. A defunctioning poly-
morphism in FCGR2B is associated with protection against malaria but susceptibility to systemic lupus
erythematosus. Proc. Natl. Acad. Sci. USA 107:7881–85
192. Niederer HA, Willcocks LC, Rayner TF, Yang W, Lau YL, et al. 2010. Copy number, linkage disequi-
librium and disease association in the FCGR locus. Hum. Mol. Genet. 19:3282–94
193. Greenwood BM. 1968. Autoimmune disease and parasitic infections in Nigerians. Lancet 2:380–82
194. Greenwood BM, Herrick EM, Voller A. 1970. Can parasitic infection suppress autoimmune disease?
Proc. R. Soc. Med. 63:19–20
195. Greenwood BM,Herrick EM, Voller A. 1970. Suppression of autoimmune disease inNZB and (NZB ×
NZW) F1 hybrid mice by infection with malaria. Nature 226:266–67
196. Larson JD, Thurman JM, Rubtsov AV, Claypool D, Marrack P, et al. 2012. Murine gammaherpesvirus
68 infection protects lupus-prone mice from the development of autoimmunity. Proc. Natl. Acad. Sci.
USA 109:E1092–100
197. Lemaitre B, Hoffmann J. 2007. The host defense ofDrosophila melanogaster.Annu. Rev. Immunol. 25:697–
743
198. Jaramillo-Gutierrez G, Molina-Cruz A, Kumar S, Barillas-Mury C. 2010. The Anopheles gambiae oxi-
dation resistance 1 (OXR1) gene regulates expression of enzymes that detoxify reactive oxygen species.
PLoS ONE 5:e11168
199. Kumar S, Molina-Cruz A, Gupta L, Rodrigues J, Barillas-Mury C. 2010. A peroxidase/dual oxidase
system modulates midgut epithelial immunity in Anopheles gambiae. Science 327:1644–48
200. Pham LN, Dionne MS, Shirasu-Hiza M, Schneider DS. 2007. A specific primed immune response in
Drosophila is dependent on phagocytes. PLoS Pathog. 3:e26
201. Roth O, Sadd BM, Schmid-Hempel P, Kurtz J. 2009. Strain-specific priming of resistance in the red
flour beetle, Tribolium castaneum. Proc. Biol. Sci. 276:145–51
202. Raulet DH. 2009. Natural killer cells: remembrances of things past. Curr. Biol. 19:R294–96
203. Sun JC, Beilke JN, Lanier LL. 2009. Adaptive immune features of natural killer cells.Nature 457:557–61
204. Sun JC, Lanier LL. 2009. Natural killer cells remember: an evolutionary bridge between innate and
adaptive immunity? Eur. J. Immunol. 39:2059–64
205. Rodrigues J, Brayner FA, Alves LC, Dixit R, Barillas-Mury C. 2010. Hemocyte differentiation mediates
innate immune memory in Anopheles gambiae mosquitoes. Science 329:1353–55
206. Luckhart S, Vodovotz Y, Cui L, Rosenberg R. 1998. The mosquito Anopheles stephensi limits malaria
parasite development with inducible synthesis of nitric oxide. Proc. Natl. Acad. Sci. USA 95:5700–5
207. Han YS, Thompson J, Kafatos FC, Barillas-Mury C. 2000. Molecular interactions between Anopheles
stephensi midgut cells and Plasmodium berghei: the time bomb theory of ookinete invasion of mosquitoes.
EMBO J. 19:6030–40
208. Han YS, Barillas-Mury C. 2002. Implications of Time Bombmodel of ookinete invasion of midgut cells.
Insect Biochem. Mol. Biol. 32:1311–16
209. Kumar S, Gupta L, Han YS, Barillas-Mury C. 2004. Inducible peroxidases mediate nitration of Anopheles
midgut cells undergoing apoptosis in response to Plasmodium invasion. J. Biol. Chem. 279:53475–82
210. Kumar S, Barillas-Mury C. 2005. Ookinete-induced midgut peroxidases detonate the time bomb in
anopheline mosquitoes. Insect Biochem. Mol. Biol. 35:721–27
211. Pfeiffer S, Lass A, Schmidt K, Mayer B. 2001. Protein tyrosine nitration in cytokine-activated murine
macrophages. Involvement of a peroxidase/nitrite pathway rather than peroxynitrite. J. Biol. Chem.
276:34051–58
212. ButPG,Murav’evRA, FominaVA,RogovinVV. 2004. [Oxides of nitrogen (NO• andNO2−) as cofactors
of the myeloperoxidase system]. Izv. Akad. Nauk Ser. Biol. 2004(3):269–73 (in Russian)



















































































IY32CH06-Pierce ARI 13 February 2014 11:33
213. Povelones M, Waterhouse RM, Kafatos FC, Christophides GK. 2009. Leucine-rich repeat protein
complex activates mosquito complement in defense against Plasmodium parasites. Science 324:258–61
214. Fraiture M, Baxter RH, Steinert S, Chelliah Y, Frolet C, et al. 2009. Two mosquito LRR proteins
function as complement control factors in the TEP1-mediated killing of Plasmodium. Cell Host Microbe
5:273–84
215. Blandin S, Shiao SH, Moita LF, Janse CJ, Waters AP, et al. 2004. Complement-like protein TEP1 is a
determinant of vectorial capacity in the malaria vector Anopheles gambiae. Cell 116:661–70
216. Oliveira GA, Lieberman J, Barillas-Mury C. 2012. Epithelial nitration by a peroxidase/NOX5 system
mediates mosquito antiplasmodial immunity. Science 335:856–59
217. Waterhouse RM, Kriventseva EV, Meister S, Xi Z, Alvarez KS, et al. 2007. Evolutionary dynamics of
immune-related genes and pathways in disease-vector mosquitoes. Science 316:1738–43
218. Christophides GK, Zdobnov E, Barillas-Mury C, Birney E, Blandin S, et al. 2002. Immunity-related
genes and gene families in Anopheles gambiae. Science 298:159–65
219. Zdobnov EM, von Mering C, Letunic I, Torrents D, Suyama M, et al. 2002. Comparative genome and
proteome analysis of Anopheles gambiae and Drosophila melanogaster. Science 298:149–59
220. Barillas-MuryC,HanYS, SeeleyD,Kafatos FC. 1999.Anopheles gambiaeAg-STAT, a new insectmember
of the STAT family, is activated in response to bacterial infection. EMBO J. 18:959–67
221. Barillas-Mury C, Charlesworth A, Gross I, Richman A, Hoffmann JA, Kafatos FC. 1996. Immune factor
Gambif1, a new rel familymember from the humanmalaria vector,Anopheles gambiae.EMBO J. 15:4691–
701
222. Frolet C, Thoma M, Blandin S, Hoffmann JA, Levashina EA. 2006. Boosting NF-κB-dependent basal
immunity of Anopheles gambiae aborts development of Plasmodium berghei. Immunity 25:677–85
223. Garver LS, Dong Y,DimopoulosG. 2009. Caspar controls resistance to Plasmodium falciparum in diverse
anopheline species. PLoS Pathog. 5:e1000335
224. Garver LS, Bahia AC, Das S, Souza-Neto JA, Shiao J, et al. 2012. Anopheles Imd pathway factors and
effectors in infection intensity-dependent anti-Plasmodium action. PLoS Pathog. 8:e1002737
225. Manske M, Miotto O, Campino S, Auburn S, Almagro-Garcia J, et al. 2012. Analysis of Plasmodium
falciparum diversity in natural infections by deep sequencing. Nature 487:375–79
226. Nsango SE, Pompon J, Xie T, Rademacher A, Fraiture M, et al. 2013. AP-1/Fos-TGase2 axis mediates
wounding-induced Plasmodium falciparum killing in Anopheles gambiae. J. Biol. Chem. 288:16145–54
227. Ramirez JL, Garver LS, Brayner FA, Alves LC, Rodrigues J, et al. 2013. The role of hemocytes in
Anopheles gambiae antiplasmodial immunity. J. Innate Immun. In press. doi: 10.1159/000353765
228. Garver LS,OliveiraGA, Barillas-MuryC. 2013. The JNKpathway is a keymediator ofAnopheles gambiae
antiplasmodial immunity. PLoS Pathog. 9:e1003622
229. Gupta L, Molina-Cruz A, Kumar S, Rodrigues J, Dixit R, et al. 2009. The STAT pathway mediates
late-phase immunity against Plasmodium in the mosquito Anopheles gambiae. Cell Host Microbe 5:498–507
230. Dong Y, Cirimotich CM, Pike A, Chandra R, Dimopoulos G. 2012. AnophelesNF-κB-regulated splicing
factors direct pathogen-specific repertoires of the hypervariable pattern recognition receptor AgDscam.
Cell Host Microbe 12:521–30
231. Dong Y, Taylor HE, Dimopoulos G. 2006. AgDscam, a hypervariable immunoglobulin domain-
containing receptor of the Anopheles gambiae innate immune system. PLoS Biol. 4:e229























































































Remembrance of Immunology Past: Conversations with Herman Eisen
Herman N. Eisen and Sondra Schlesinger                                                     1
HLA-B27
Paul Bowness                                                                                   29
Inflammasome-Independent Regulation of IL-1-Family Cytokines
Mihai G. Netea, Frank L. van de Veerdonk, Jos W.M. van der Meer,
Charles A. Dinarello, and Leo A.B. Joosten                                               49
Programmed Necrosis in the Cross Talk of Cell Death and Inflammation
Francis Ka-Ming Chan, Nivea Farias Luz, and Kenta Moriwaki                         79
Endoplasmic Reticulum Stress in Immunity
Sarah E. Bettigole and Laurie H. Glimcher                                                107
Insights into Cytokine–Receptor Interactions from Cytokine Engineering
Jamie B. Spangler, Ignacio Moraga, Juan L. Mendoza, and K. Christopher Garcia    139
T Cell Antigen Receptor Recognition of Antigen-Presenting Molecules
Jamie Rossjohn, Stephanie Gras, John J. Miles, Stephen J. Turner,
Dale I. Godfrey, and James McCluskey                                                  169
Immunity to Helminths: Resistance, Regulation, and Susceptibility to
Gastrointestinal Nematodes
Richard K. Grencis                                                                           201
Microbiota-Mediated Inflammation and Antimicrobial Defense in the
Intestine
Silvia Caballero and Eric G. Pamer                                                         227
Innate Immune Pattern Recognition: A Cell Biological Perspective
Sky W. Brubaker, Kevin S. Bonham, Ivan Zanoni, and Jonathan C. Kagan            257
Ion Channels in Innate and Adaptive Immunity
Stefan Feske, Heike Wulff, and Edward Y. Skolnik                                        291
TAM Receptor Signaling in Immune Homeostasis
Carla V. Rothlin, Eugenio A. Carrera-Silva, Lidia Bosurgi, and Sourav Ghosh        355
Structural Biology of Innate Immunity




















































































IY33-Frontmatter ARI 23 March 2015 20:35
The Immunobiology of Interleukin-27
Hiroki Yoshida and Christopher A. Hunter                                                 417
Innate Immune Recognition of Cancer
Seng-Ryong Woo, Leticia Corrales, and Thomas F. Gajewski                             445
Natural Antibody Repertoires: Development and Functional Role in
Inhibiting Allergic Airway Disease
John F. Kearney, Preeyam Patel, Emily K. Stefanov, and R. Glenn King                475
Transcription Factor Networks Directing the Development, Function,
and Evolution of Innate Lymphoid Effectors
Joonsoo Kang and Nidhi Malhotra                                                          505
Early T Cell Activation: Integrating Biochemical, Structural,
and Biophysical Cues
Bernard Malissen and Pierre Bongrand                                                     539
The Varieties of Immunological Experience: Of Pathogens,
Stress, and Dendritic Cells
Bali Pulendran                                                                                563
Transcriptional Regulation of Innate and Adaptive Lymphocyte Lineages
Maria Elena De Obaldia and Avinash Bhandoola                                         607
Macrophages: Development and Tissue Specialization
Chen Varol, Alexander Mildner, and Steffen Jung                                        643
Dynamic Tuning of Lymphocytes: Physiological Basis, Mechanisms,
and Function
Zvi Grossman and William E. Paul                                                        677
Stromal Cells in Chronic Inflammation and Tertiary Lymphoid
Organ Formation
Christopher D. Buckley, Francesca Barone, Saba Nayar, Cecile Be´ne´zech,
and Jorge Caaman˜o                                                                       715
Interleukin-22: Immunobiology and Pathology
Jarrod A. Dudakov, Alan M. Hanash, and Marcel R.M. van den Brink                747
The Immunology of Epstein-Barr Virus–Induced Disease
Graham S. Taylor, Heather M. Long, Jill M. Brooks, Alan B. Rickinson,
and Andrew D. Hislop                                                                    787
Molecular Mechanisms in Genetically Defined Autoinflammatory Diseases:
Disorders of Amplified Danger Signaling
Adriana Almeida de Jesus, Scott W. Canna, Yin Liu,
and Raphaela Goldbach-Mansky                                                          823
vi Contents
A
nn
u.
 R
ev
. I
m
m
un
ol
. 2
01
4.
32
:1
57
-1
87
. D
ow
nl
oa
de
d 
fro
m
 w
w
w
.an
nu
al
re
vi
ew
s.o
rg
 
A
cc
es
s p
ro
vi
de
d 
by
 W
IB
64
17
 - 
M
ax
-P
la
nc
k-
G
es
el
lsc
ha
ft 
on
 0
6/
30
/2
0.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
